Page last updated: 2024-10-29

ifosfamide and Carcinoma, Epidermoid

ifosfamide has been researched along with Carcinoma, Epidermoid in 173 studies

Research Excerpts

ExcerptRelevanceReference
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."7.81Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."7.69[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."7.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus."5.08A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998)
" A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin."3.81Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015)
"The stage-by-stage prognosis for cervical cancer patients has not improved in the past decades."3.77Neoadjuvant therapy for cervical cancer. ( Achterrath, W; Eiermann, W; Kuehnle, H; Meerpohl, HG, 1992)
" Three courses with cisplatin 75 mg/m(2), paclitaxel 175 mg/m(2) and ifosfamide 5 g/m(2) (epirubicin 80 mg/m(2) in adenocarcinoma) were followed by cold-knife conization and pelvic lymphadenectomy."3.74Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. ( Bonazzi, C; Chiari, S; Maneo, A; Mangioni, C, 2008)
"The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC)."3.69Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer. ( Darnton, SJ; Ferry, DR; Jenner, K; Matthews, HR; Steyn, RS, 1995)
"Generalized and partial seizures with secondary generalization were observed during ifosfamide-mesna (IFO) treatment in a patient with lung epidermoid carcinoma."3.69[Epileptic seizures and treatment with ifosfamide-mesna]. ( Farisse, P; Somma-Mauvais, H; Viallat, JR, 1994)
"Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases."3.68Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993)
"Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)."3.66[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983)
"Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone."2.75Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. ( Daliani, D; Kincaid, M; Osai, W; Pagliaro, LC; Pettaway, CA; Thall, PF; Wen, S; Williams, DL; Williams, MB, 2010)
"Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient."2.73Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008)
"Ifosfamide is an active alkylating agent used in the first-line treatment of NSCLC."2.71Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. ( Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM, 2003)
" Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity."2.71A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. ( Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004)
"Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy."2.71[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. ( Gorchev, G; Kornovski, Ia, 2003)
"All of the patients had biopsy-proven squamous cell carcinoma of the uterine cervix."2.71Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer. ( Abe, Y; Aida, T; Akahira, J; Aoki, M; Ito, K; Katahira, A; Kitamura, T; Niikura, H; Okamura, C; Okamura, K; Otsuki, K; Saito, S; Sato, N; Takano, T; Utsunomiya, H; Yaegashi, N, 2004)
"Megestrol acetate 250 mg PO was administered throughout the duration of chemotherapy."2.69A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. ( Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H, 1998)
"Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4."2.69Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. ( Abad, T; Alvárez, I; Churruca, C; Egana, L; Guimón, E; Lacasta, A; López de Argumedo, G; Paredes, A; Piera, JM; Sánchez Parra, M, 1999)
"A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus."2.68[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. ( Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997)
"All patients were required to have squamous cell carcinoma of the head and neck that had recurred following surgery or radiotherapy or both."2.68A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. ( Benner, SE; Dimery, IW; Dunnington, JS; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1996)
"Granulocytopenia was the dose-limiting toxicity."2.68Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. ( Benner, SE; Hong, WK; Huber, MH; Lippman, SM, 1995)
"The early stages of bronchial carcinoma are still a domain of operative treatment."2.68[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995)
"Thirty patients with advanced squamous cell carcinoma of the cervix were included in a phase II study with cisplatin (DDP) and ifosfamide (IF)/mesna."2.68Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. ( Araujo, CE; Cervellino, JC; Miles, H; Nishihama, A; Sánchez, O, 1995)
"A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i."2.67Ifosfamide in advanced epidermoid head and neck cancer. ( Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J, 1993)
"Neo-adjuvant therapy with MIC in squamous carcinoma of the oesophagus has shown encouraging early results, with acceptable toxicity."2.67A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Darnton, SJ; Duffy, JP; Matthews, HR; Walker, SJ, 1994)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."2.67Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
" The major dose-limiting toxic effect of CIA was leukopenia."2.64Protection against chemotherapy toxicity by IV hyperalimentation. ( Bodey, GP; Copeland, EW; Dudrick, SJ; Freireich, EJ; Issell, BF; Valdivieso, M; Zaren, HA, 1978)
"Ifosfamide (IFO) has demonstrated activity in recurrent/metastatic squamous cell head and neck carcinoma with an overall response rate of 24-26%."2.42Ifosfamide in the treatment of head and neck cancer. ( Airoldi, M; Bumma, C; Cortesina, G; Giordano, C; Pedani, F, 2003)
"Patients with advanced squamous cell head and neck cancer have a dismal long-term survival rate not only because of metastatic disease, but also primarily because of failure in local disease control."2.41Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. ( Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM, 2000)
"Paclitaxel has been tested with interesting results in cervical cancer."2.41Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. ( Fei, F; Mangioni, C; Zanetta, G, 2000)
" The Eastern Cooperative Oncology Group is currently evaluating high-dose (200 mg/m2) and low-dose (135 mg/m2) paclitaxel in combination with cisplatin to assess dose-response effects, toxicity, and efficacy."2.39Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. ( Forastiere, AA; Urba, SG, 1995)
"We report a case of metastatic penile cancer refractory to TIP chemotherapy, with a dramatic treatment response to ipilimumab and nivolumab."1.62Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. ( Baweja, A; Mar, N, 2021)
" In this study, we adjusted the dosage of the triplet regimen and introduced carboplatin in cisplatin-intolerable patients."1.48Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. ( Bae, DS; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES, 2018)
"Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries."1.42Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. ( Boraska Jelavić, T; Hamm, W; Hrepić, D; Petrić Miše, B; Prskalo, T; Strikic, A; Tomić, K; Tomić, S; Vrdoljak, E, 2015)
"Standard treatment of cervical cancer FIGO stage IB1 is a radical hysterectomy with pelvic lymphadenectomy."1.42Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. ( Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I, 2015)
"Standard chemotherapy for advanced penile cancer has not been established because of its rarity."1.42[Dramatic response of penile cancer with inguinal lymph node metastases to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin : a case report]. ( Arakawa, H; Deguchi, T; Horie, K; Kato, H; Kubota, Y; Matsuoka, K; Nagai, S; Nakano, M, 2015)
"Downstaging by NAC in IB1 and IB2 cervical cancer before fertility-sparing surgery is still an experimental procedure, but shows some promise."1.40Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. ( Halaska, MJ; Lisy, J; Matecha, J; Pluta, M; Rob, L; Robova, H; Skapa, P, 2014)
"The management of advanced cervical cancer is challenging."1.40Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report. ( Siesto, G; Vitobello, D, 2014)
" Our patient was subsequently enrolled on a phase 1 clinical trial of a novel, orally bioavailable bromodomain and extra terminal inhibitor, GSK525762 (NCT01587703)."1.39NUT midline carcinoma: an aggressive intrathoracic neoplasm. ( Costello, BA; Dronca, RS; French, CA; Hilton, J; Marks, RS; Molina, JR; Nerby, CL; Parikh, SA; Peddareddigari, VG; Roden, AC; Shapiro, GI, 2013)
"The role of chemotherapy (CHX) in squamous cell carcinoma of the head and neck (SCCHN) has been expanding."1.38The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent. ( Ekblad, L; Kjellén, E; Mineta, H; Sasaki, Y; Wahlberg, P; Wennerberg, J, 2012)
"Pure primary squamous cell carcinoma (SCC) of the breast is rare and difficult to treat."1.35Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. ( Bhatt, L; Fernando, I, 2009)
"In 20."1.35A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery. ( Doval, DC; Kumar, JV; Rao, R; Rawal, S, 2009)
"For patients with stage II to IV laryngeal cancer, radiation therapy (RT) either alone or with concurrent chemotherapy provides the highest rate of organ preservation but can be associated with functional impairment."1.35Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. ( Ark, N; Diaz, EM; El-Naggar, AK; Garden, AS; Gillenwater, AM; Ginsberg, LE; Glisson, BS; Holsinger, FC; Khuri, FR; Ki Hong, W; Kies, MS; Lee, JJ; Lewin, JS; Lin, HY; Shin, DM, 2009)
"The prognosis of recurrent metastatic cervical cancer is extremely poor."1.34Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. ( Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F, 2007)
"Human-derived head-and-neck squamous cell carcinoma xenografts (implanted in nude mice/nine groups of 10 mice) were treated with various treatment modalities and combinations of them (radiation with 5 x 2 or 10 x 2 Gy, hyperthermia at 41 degrees C or 41."1.31Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival. ( Feyerabend, T; Ressel, A; Weiss, C, 2001)
"43 patients with Stage IV squamous cell carcinoma of the head and neck have been treated neoadjuvantly with two cycles chemotherapy (ifosfamide 1."1.31[The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer]. ( Christoph, B; Esser, E; Hartlapp, J; Hermann, RM; Krech, R; Müller, MK; Wagner, W, 2001)
"The response rate was higher in squamous cell carcinomas (85%) than adenocarcinomas or adenosquamous carcinomas (67%)."1.30[Neoadjuvant chemotherapy for advanced cervical cancer]. ( Hongo, A; Ikuhashi, H; Kobashi, Y; Kodama, J; Kudo, T; Miyagi, Y; Mizutani, Y; Okuda, H; Yoshinouchi, M, 1999)
"Seven oesophageal squamous carcinomas, treated with pre-operative chemotherapy (mitomycin-C, ifosfamide and cisplatin-MIC), with a course finishing 21 days prior to resection, were examined by electronmicroscopy."1.29Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma. ( Antonakopoulos, GN; Darnton, SJ; Duffy, JP; Matthews, HR; Newman, J, 1994)
"Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease."1.28A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990)
"Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC)."1.28Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer. ( Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M, 1992)
"The authors report a case of pulmonary squamous cell carcinoma which occurred after chemotherapy of non-Hodgkin's lymphoma (NHL)."1.28[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma]. ( Annoh, S; Arai, N; Kaneko, H; Shirai, T; Tsukahara, T; Umeda, M, 1992)
"Thirty-one patients with inoperable squamous cell carcinoma of the lung were treated with a combination of cis-platin (CDDP, 100 mg/m2 day 1), ifosfamide (IFX, 2 g/m2 day 1, 2, 3; with mesna) and vindesine (VDS, 3 mg/m2 day 1)."1.28[Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"Survival in patients with advanced cervical cancer (stage III B) treated by radical radiotherapy is low."1.28Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma. ( Garcia-Puche, JL; Lara, PC; Pedraza, V, 1990)
"The tumors included 5 squamous cell carcinomas (non keratinizing: 2, keratinizing: 3), two adenosquamous (including one glassy cell carcinoma), one adenocarcinoma (endometrioid type) and one argyrophil cell carcinoma."1.28Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix. ( Arimatsu, T; Izumi, S; Matsumura, T; Nagano, H; Nagasue, N; Nishida, T; Okura, N; Yakushiji, M, 1989)
"Thirty patients with advanced squamous carcinoma of the uterine cervix recurrent after radiotherapy or surgery and refractory to first-line chemotherapeutic agents were treated with ifosfamide in a dose of 1."1.28Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; DeEulis, T; Sutton, GP; Webster, KD, 1989)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."1.28Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989)
"The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated."1.27[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984)
" Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients."1.27A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. ( Coleman, RE; Gallagher, C; Harper, PG; Osborne, R; Rankin, EM; Silverstone, AC; Slevin, ML; Souhami, RL; Tobias, JS; Trask, CW, 1986)
"The most frequent histology was squamous cell carcinoma found in 20 patients."1.27[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985)
"The etoposide combination was tolerated better."1.27Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer. ( Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P, 1986)
"Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression."1.27Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. ( Eisenberger, M; Kelsen, DP; Lipperman, R; Nanus, DM, 1988)
"Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4."1.26Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978)

Research

Studies (173)

TimeframeStudies, this research(%)All Research%
pre-199036 (20.81)18.7374
1990's58 (33.53)18.2507
2000's47 (27.17)29.6817
2010's31 (17.92)24.3611
2020's1 (0.58)2.80

Authors

AuthorsStudies
Baweja, A1
Mar, N1
Karageorgopoulou, S1
Kostakis, ID1
Gazouli, M1
Markaki, S1
Papadimitriou, M1
Bournakis, E1
Dimopoulos, MA2
Papadimitriou, CA1
Choi, HJ1
Paik, ES1
Choi, CH1
Kim, TJ1
Lee, YY1
Lee, JW1
Bae, DS1
Kim, BG1
Xu, J1
Li, G1
Zhu, SM1
Cai, QL1
Wang, Z1
Yang, X2
Zhang, HT1
Niu, YJ1
Pinkavova, I1
Fischerova, D1
Zikan, M1
Burgetova, A1
Slama, J1
Svarovsky, J1
Dundr, P1
Dusek, L1
Cibula, D1
Siesto, G2
Vitobello, D2
Ozdemir, O1
Ozdemir, P1
Veral, A1
Uluer, H1
Ozhan, MH1
Ma, K1
Yang, YH1
Feng, ZY1
Liu, TY1
Wen, HW1
Liao, QP1
Parikh, SA1
French, CA1
Costello, BA1
Marks, RS1
Dronca, RS1
Nerby, CL1
Roden, AC1
Peddareddigari, VG1
Hilton, J1
Shapiro, GI1
Molina, JR1
Vizza, E1
Corrado, G1
Zanagnolo, V2
Tomaselli, T1
Cutillo, G1
Mancini, E1
Maggioni, A2
Khawandanah, M1
Baxley, A1
Pant, S1
Robova, H1
Halaska, MJ1
Pluta, M1
Skapa, P1
Matecha, J1
Lisy, J1
Rob, L1
Petrić Miše, B1
Boraska Jelavić, T1
Strikic, A1
Hrepić, D1
Tomić, K1
Hamm, W3
Tomić, S1
Prskalo, T3
Vrdoljak, E3
Kubota, Y1
Nakano, M1
Nagai, S1
Matsuoka, K1
Arakawa, H1
Horie, K1
Deguchi, T1
Kato, H1
Scandurra, G1
Scibilia, G1
Banna, GL1
D'Agate, G1
Lipari, H1
Gieri, S1
Scollo, P2
Gakis, G1
Morgan, TM1
Daneshmand, S1
Keegan, KA1
Todenhöfer, T1
Mischinger, J1
Schubert, T1
Zaid, HB1
Hrbacek, J1
Ali-El-Dein, B1
Clayman, RH1
Galland, S1
Olugbade, K1
Rink, M1
Fritsche, HM1
Burger, M1
Chang, SS1
Babjuk, M1
Thalmann, GN1
Stenzl, A1
Efstathiou, JA1
Salihi, R1
Leunen, K1
Van Limbergen, E1
Moerman, P1
Neven, P1
Vergote, I1
Zwenger, AO1
Grosman, G1
Iturbe, J1
Leone, J1
Vallejo, CT2
Leone, JP1
Verdera, PP1
Pérez, JE2
Leone, BA2
Minig, L1
Cárdenas-Rebollo, JM1
Colombo, N5
Hancock, SB1
Krempl, GA1
Canfield, V1
Bogardus, C1
Kojouri, K1
Kaneaster, SK1
Medina, JE1
Rivera, F1
Eugenia Vega-Villegas, M1
López, C1
Francisca López-Brea, M1
Rubio, A1
Del Valle, A1
García-Reija, F1
García-Montesinos, B1
Rodríguez-Iglesias, J1
Hinojo, C1
Márquez, R1
Angel Alonso-Bermejo, M1
Salcedo, M1
Blanco, Y1
Vega, N1
López-Tarruella, S1
Sanz-Ortiz, J1
Maneo, A1
Chiari, S2
Bonazzi, C1
Mangioni, C4
Lissoni, AA1
Pellegrino, A2
Parma, G2
Zola, P2
Katsaros, D2
Buda, A2
Landoni, F2
Peiretti, M1
Dell'anna, T1
Fruscio, R1
Signorelli, M1
Grassi, R1
Floriani, I2
Fossati, R2
Torri, V2
Rulli, E1
Holsinger, FC1
Kies, MS2
Diaz, EM1
Gillenwater, AM2
Lewin, JS1
Ginsberg, LE1
Glisson, BS7
Garden, AS1
Ark, N1
Lin, HY1
Lee, JJ3
El-Naggar, AK2
Ki Hong, W1
Shin, DM9
Khuri, FR8
Kumar, JV1
Doval, DC1
Rao, R1
Rawal, S1
Bhatt, L1
Fernando, I1
Saba, NF1
Choi, M1
Muller, S1
Shin, HJ1
Tighiouart, M1
Papadimitrakopoulou, VA1
Chen, ZG1
Specenier, PM1
Van Den Brande, J1
Schrijvers, D1
Huizing, MT1
Altintas, S1
Dyck, J1
Van Den Weyngaert, D1
Van Laer, C1
Vermorken, JB1
Pagliaro, LC1
Williams, DL1
Daliani, D1
Williams, MB1
Osai, W1
Kincaid, M1
Wen, S1
Thall, PF1
Pettaway, CA1
Downs, LS1
Chura, JC1
Argenta, PA1
Judson, PL1
Ghebre, R1
Geller, MA1
Carson, LF1
Huang, YC1
Chang, PM1
Chen, MH1
Chu, PY1
Tzeng, CH1
Chang, SY1
Yang, MH1
Zheng, M1
Huang, L1
Liu, JH1
Xiong, Y1
Li, JD1
Huang, X1
He, L1
Ren, YF1
Wang, HY1
Wang, Y1
Wang, G1
Wei, LH1
Huang, LH1
Wang, JL1
Wang, SJ1
Li, XP1
Shen, DH1
Bao, DM1
Gao, J1
Sasaki, Y1
Kjellén, E1
Ekblad, L1
Wahlberg, P1
Mineta, H1
Wennerberg, J1
Gong, L1
Lou, JY1
Wang, P1
Zhang, JW1
Liu, H1
Peng, ZL1
Wang, PL1
Cheng, YB1
Kuerban, G1
Hasegawa, K1
Okamoto, H1
Kawamura, K1
Kato, R1
Kobayashi, Y1
Sekiya, T1
Udagawa, Y1
Vercellino, GF1
Piek, JM1
Schneider, A1
Köhler, C1
Mangler, M1
Speiser, D1
Chiantera, V1
Mouillet, G1
Monnet, E1
Milleron, B1
Puyraveau, M1
Quoix, E1
David, P1
Ducoloné, A1
Molinier, O1
Zalcman, G1
Depierre, A1
Westeel, V1
Dede, DS1
Aksoy, S1
Cengiz, M1
Gullu, I1
Altundag, K1
Pirovano, C1
Ieda, N1
Lippman, SM8
Ginsberg, L4
Diaz, E1
Papadimitrakopoulou, V2
Feng, L1
Francisco, M1
Garden, A1
Myers, J1
Clayman, G2
Hong, WK9
Gebbia, V1
Galetta, D1
Caruso, M1
Verderame, F1
Pezzella, G1
Valdesi, M1
Borsellino, N1
Pandolfo, G1
Durini, E1
Rinaldi, M1
Loizzi, M1
Gebbia, N1
Valenza, R1
Tirrito, ML1
Varvara, F1
Colucci, G1
Chen, YM1
Shih, JF1
Lee, CS1
Chen, MC1
Lin, WC2
Tsai, CM2
Perng, RP2
Haddad, R1
Posner, M1
Fujita, A3
Ohkubo, T1
Hoshino, H1
Takabatake, H1
Tagaki, S1
Sekine, K2
Abe, S1
Darnton, SJ6
Archer, VR1
Stocken, DD1
Mulholland, PJ1
Casson, AG1
Ferry, DR2
Airoldi, M1
Cortesina, G1
Giordano, C1
Pedani, F1
Bumma, C1
Cavaletti, G1
Bogliun, G1
Marzorati, L1
Zincone, A1
Piatti, M1
Lissoni, A3
Fei, F3
Cundari, S1
Zanna, C1
Sculier, JP1
Lafitte, JJ1
Berghmans, T1
Van Houtte, P1
Lecomte, J1
Thiriaux, J1
Efremidis, A1
Koumakis, G1
Giner, V1
Richez, M1
Corhay, JL1
Wackenier, P1
Lothaire, P1
Paesmans, M1
Mommen, P1
Ninane, V1
Omrcen, T2
Gorchev, G1
Kornovski, Ia1
Aoki, M1
Akahira, J1
Niikura, H1
Saito, S1
Abe, Y1
Aida, T1
Sato, N1
Kitamura, T1
Otsuki, K1
Katahira, A1
Utsunomiya, H1
Okamura, C1
Takano, T1
Ito, K1
Okamura, K1
Yaegashi, N1
Watanabe, A1
Taniguchi, M1
Rapidis, AD1
Gakiopoulou, H1
Stavrianos, SD1
Vilos, GA1
Faratzis, G1
Douzinas, EE1
Givalos, N1
Patsouris, E1
Situm, K1
Boraska, T1
Frleta Ilić, N1
Janković, S1
Kato, D1
Achiwa, H1
Sato, S1
Bessho, Y1
Shimizu, S1
Hattori, N1
Maeda, H1
Niimi, T1
Oguri, T1
Ueda, R1
Gueli Alletti, D1
Malzoni, C1
Sartori, E1
Duck, L1
Devogelaer, JP1
Persu, A1
Berlière, M1
Caussin, E1
Baurain, JF1
Machiels, JP1
Mizuno, K1
Kidokoro, K1
Miyazaki, K1
Yoshida, K1
Nakagawa, A1
Mizuno, M1
Suzuki, S1
Kuno, N1
Furuhashi, M1
Ishizuka, T1
Ishikawa, K1
Boutemy, M1
Mispelaere, D1
Krzisch, C1
Jounieaux, V1
Galsky, MD1
Iasonos, A1
Mironov, S1
Scattergood, J1
Donat, SM1
Bochner, BH1
Herr, HW1
Russo, P1
Boyle, MG1
Bajorin, DF1
Khoury-Collado, F1
Bowes, RJ1
Jhamb, N1
Aghajanian, C1
Abu-Rustum, NR1
Ferrandina, G1
Fanfani, F1
Ludovisi, M1
Fagotti, A1
Carbone, A1
Zannoni, G1
Guerriero, M1
Petrillo, M1
Scambia, G1
Han, JQ1
Han, CY1
Bi, YH1
Park, BB1
Im, YH1
Hwang, IG1
Lee, SC1
Ahn, JS1
Ahn, MJ1
Lim, HY1
Kang, WK1
Park, K1
Recchia, F2
Candeloro, G1
Di Staso, M1
Necozione, S1
Bisegna, R1
Bratta, M1
Tombolini, V1
Rea, S2
Drings, P4
Stiefel, P3
Dirks, HP1
Grimm, V1
Kleckow, M2
Manke, HG3
Queisser, W2
Abel, U2
Heinrich, S1
Saiers, JH2
Slavik, M2
Harrison, EF1
Hawke, JE1
Hunter, HL1
Costanzi, JJ3
Morgan, LR2
Plotkin, D1
Tucker, WG1
Worrall, PM1
Hokanson, J1
Holoye, PY2
Anderson, T2
Duelge, J2
Hansen, RM2
Ritch, PS2
Bakowski, MT1
Crouch, JC1
Joss, RA1
Cavalli, F1
Goldhirsch, A1
Mermillod, B1
Brunner, KW1
Araujo, CE4
Tessler, J1
Focan, C1
Salamon, E1
Le Hung, S1
Frère, MH1
Mbuyamba, P1
Claessens, JJ1
Gad-el-Mawla, N1
Ziegler, JL1
Hamza, R1
Elserafi, M1
Khaled, H1
Matthiessen, W1
Stempinski, E1
Göbel, D1
Thalmann, U1
Kohno, I1
Kazuta, M1
Miyao, J1
Kunimi, N1
Kawamoto, M1
Tanimura, T1
Fujiwara, K1
Sekiba, K1
Issell, BF3
MacFadyen, BV1
Gum, ET1
Valdivieso, M3
Dudrick, SJ2
Bodey, GP3
Benner, SE2
Huber, MH2
Murad, AM1
Triginelli, SA1
Ribalta, JC1
Singhal, RM1
Jindel, R1
Gupta, AK1
Kumar, L2
Kaushal, R1
Nandy, M1
Biswal, BM1
Kumar, S1
Kriplani, A1
Singh, R1
Rath, GK1
Kochupillai, V1
Forastiere, AA1
Urba, SG1
Wagner, W2
von Eiff, M1
Klinke, F1
Micke, O1
Rübe, C1
Willich, N1
Zulian, GB1
Tullen, E1
Maton, B1
Cervellino, JC3
Sánchez, O2
Miles, H1
Nishihama, A1
Somma-Mauvais, H1
Farisse, P1
Viallat, JR1
Antonakopoulos, GN1
Newman, J1
Duffy, JP2
Matthews, HR5
Fanning, J1
Ladd, C1
Hilgers, RD1
Allen, SM2
Walker, SJ1
Cullen, MH3
Filtenborg, TA1
Hansen, HH1
Aage Engelholm, S1
Rørth, M1
Martín, M1
Diaz-Rubio, E1
González Larriba, JL1
Casado, A1
Sastre, J1
López-Vega, JM1
Almenarez, J1
Dominguez, S1
Edwards, CW1
Sutton, GP4
Blessing, JA6
McGuire, WP1
Patton, T1
Look, KY1
Jenner, K1
Steyn, RS2
Souquet, PJ1
Fournel, P1
Bohas, CH1
Fortune, IC1
Chatte, G1
Niehues, T1
Harms, D1
Jürgens, H1
Göbel, U1
Shirinian, M2
Dimery, IW1
Dunnington, JS1
Vansteenkiste, J1
Vandebroek, J1
Mariën, S1
Roex, L1
Bertrand, P1
Bockaert, J1
De Beukelaar, T1
Deman, R1
De Muynck, P1
Ulrichts, H1
Lokich, J1
Anderson, N1
Moore, C1
Bern, M1
Coco, F1
Dow, E1
Scagliotti, GV1
Ricardi, U1
Crinó, L1
Maranzano, E1
De Marinis, F1
Morandi, MG1
Meacci, L1
Marangolo, M1
Emiliani, E1
Rosti, G1
Figoli, F1
Bolzicco, G1
Masiero, P1
Gentile, A1
Tonato, M1
Omura, GA1
Vaccarello, L1
Berman, ML3
Clarke-Pearson, DL1
Mutch, DG1
Anderson, B1
Kyriakakis, Z1
Kostakopoulos, A1
Karayiannis, A1
Sofras, F1
Zervas, A1
Giannopoulos, A1
Dimopoulos, C1
Noda, K1
Hirabayashi, K2
Terashima, Y1
Ozaki, M1
Yakushiji, M2
Hatae, M1
Kanazawa, K1
Sur, M1
Taylor, L1
Cooper, K1
Sur, RK1
Lawhorn, K2
Sandler, A1
Saxman, S1
Bandealy, M1
Heilman, D1
Monaco, F1
McClean, J1
Arquette, M1
Ang, KK2
Clayman, GL1
Callender, DL1
Latz, D1
Schulze, T1
Manegold, C1
Schraube, P1
Flentje, M1
Weber, KJ1
McManus, KG1
McAleer, JA1
Zanetta, G2
Sessa, C1
Gueli-Alletti, D1
Kodama, J1
Ikuhashi, H1
Hongo, A1
Mizutani, Y1
Miyagi, Y1
Yoshinouchi, M1
Kobashi, Y1
Okuda, H1
Kudo, T1
Sánchez Parra, M1
Churruca, C1
Paredes, A1
Lacasta, A1
López de Argumedo, G1
Alvárez, I1
Abad, T1
Egana, L1
Guimón, E1
Piera, JM1
Levitan, N1
Dowlati, A1
Craffey, M1
Tahsildar, H1
MacKay, W1
McKenney, J1
Remick, SC1
Brücker, C1
Sieg, P2
Chen, Y1
Yang, KY1
Wu, HW1
Whang-Peng, J1
Domínguez, ME1
Machiavelli, MR1
Lacava, JA1
Romero, AO1
Ortiz, EH1
Grasso, S1
Amato, S1
Rodríguez, R1
Barbieri, M1
Romero Acuña, J1
Focaccia, G1
Suttora, G1
Scenna, M1
Boughen, JM1
Romero Acuña, LA1
Langhi, MJ1
Ressel, A1
Weiss, C1
Feyerabend, T2
Papadimitrakopoulou, VM1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Sommer, K1
Peters, SO1
Robins, IH1
Raap, M1
Wiedemann, GJ1
Remmert, S1
Bittner, C1
Hermann, RM1
Krech, R1
Hartlapp, J1
Esser, E1
Christoph, B1
Müller, MK1
Lalli, A1
Lombardo, M1
De Filippis, S1
Saggio, G1
Fabbri, F1
Rosselli, M1
Capomolla, E1
Bloss, JD1
Behrens, BC1
Mannel, RS1
Rader, JS1
Sood, AK1
Markman, M1
Benda, J1
Zaren, HA1
Freireich, EJ1
Copeland, EW1
Gagliano, R1
Loukas, D1
Panettiere, FJ1
Hokanson, JA1
Hersh, EM1
Richman, S1
Gutterman, JU1
Tay, SK1
Lai, FM1
Soh, LT1
Ho, TH1
Ang, PT1
Au, E1
Lee, JS1
Dhingra, HH1
Greenberg, J1
Okada, E1
Nakazuma, Y1
Akamatsu, Y1
Sezaki, H1
Ohta, M1
Nakanishi, Y1
Buxton, EJ4
Kuehnle, H1
Meerpohl, HG1
Eiermann, W2
Achterrath, W1
Arai, N1
Annoh, S1
Kaneko, H1
Umeda, M1
Tsukahara, T1
Shirai, T1
Saunders, N1
Blackledge, GR1
Kelly, K1
Redman, CW1
Monaghan, J2
Paterson, ME1
Luesley, DM1
Bhargava, VL1
Hannigan, EV1
Dinh, TV1
Doherty, MG1
Pirisi, C2
Francia, A1
Cerruti, R1
Inoue, Y2
Sasaki, H1
Nakajima, S1
Honda, R2
Asakawa, M2
Suzuki, A2
Brosto, M1
Rossi, R1
Photopulos, G2
Homesley, HD2
Fujii, M1
Segawa, Y1
Matsutomo, S1
Genba, K1
Paccagnella, A1
Favaretto, A1
Brandes, A1
Ghiotto, C1
Fornasiero, A1
Volpi, A1
Pappagallo, G1
Festi, G1
Cipriani, A1
Vinante, O1
Coleman, RE2
Clarke, JM1
Slevin, ML2
Sweetenham, J1
Williams, CJ1
Blake, P1
Calman, F1
Wiltshaw, E1
Harper, PG2
Lara, PC1
Garcia-Puche, JL1
Pedraza, V1
Barton, C1
Blackledge, G3
Mould, JJ3
Meanwell, CA3
Paterson, M1
Tobias, J1
Alcock, C1
Spooner, D2
Nishida, T1
Nagasue, N1
Arimatsu, T1
Nagano, H1
Izumi, S1
Okura, N1
Matsumura, T1
Ansell, SM1
Alberts, AS1
Falkson, G1
Adcock, L1
Webster, KD1
DeEulis, T1
Meier, W1
Stieber, P1
Fateh-Moghadam, A1
Hepp, H1
Ardizzoni, A1
Fusco, V1
Gulisano, M1
Pronzato, P1
Baracco, F1
Capaccio, A1
Pastorino, G1
Nosenzo, M1
Felletti, R1
Fabiano, F1
Ohnoshi, T1
Hiraki, S1
Ueoka, H1
Tamura, T1
Kawahara, S1
Yonei, T1
Yamashita, H1
Ishii, J1
Tamai, M1
Egawa, T1
Becker, H1
Bülzebruck, H2
Djawid, N1
Ruchalla, E1
Tessen, HW1
Paschke, R1
Worst, P1
Brust, J1
Banks, J1
Anderson, EG1
Smith, AP1
Gatzemeier, U1
Hossfeld, DK1
Radenbach, D1
Zschaber, R1
Lawton, FG1
Stuart, NS1
Kavanagh, J1
Latief, TN1
Chetiyawardana, AD1
Nanus, DM1
Kelsen, DP1
Lipperman, R1
Eisenberger, M1
Verweij, J1
Alexieva-Figusch, J1
de Boer, MF1
Reichgelt, B1
Stoter, G1
Gallagher, C1
Osborne, R1
Rankin, EM1
Silverstone, AC1
Souhami, RL1
Tobias, JS1
Trask, CW1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers[NCT01587703]Phase 1196 participants (Actual)Interventional2012-03-28Completed
Prospective Study for the Validation of the Genetic Signature 354849 to Predict the Response to Standard Treatment in Patients With Locally Advanced Cervical Cancer[NCT04067882]189 participants (Anticipated)Observational2019-09-30Recruiting
Multicenter Prospective Randomized Study on NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Patients With Cervical Cancer FIGO Stage IB2 and IIB[NCT02422563]Phase 3534 participants (Anticipated)Interventional2015-10-31Not yet recruiting
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831]Phase 20 participants (Actual)Interventional2016-02-29Withdrawn (stopped due to Industry decline to supply study drug)
A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis[NCT00512096]Phase 230 participants (Actual)Interventional1999-08-31Completed
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602]Phase 237 participants (Anticipated)Interventional2019-08-01Recruiting
Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC[NCT00198354]Phase 3530 participants (Actual)Interventional2001-05-31Completed
"Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652]Phase 3230 participants (Anticipated)Interventional2015-07-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

InterventionPer hour (Geometric Mean)
GSK525762 80 mg Amorphous+6 mg Stable Isotope5.628
GSK525762 80 mg Besylate+6 mg Stable Isotope5.176
GSK525762 30 mg Besylate+6 mg Stable Isotope5.088
GSK525762 80 mg Besylate Fed5.954

Maximum Observed Concentration (Cmax) of GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

InterventionNanograms per milliliter (Geometric Mean)
GSK525762 80 mg Amorphous+6 mg Stable Isotope1431.41
GSK525762 80 mg Besylate+6 mg Stable Isotope1483.21
GSK525762 30 mg Besylate+6 mg Stable Isotope655.33
GSK525762 80 mg Besylate Fed1305.59

Number of Participants With Dose Reductions or Delays-Besylate Sub-study

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionParticipants (Count of Participants)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes3
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes1

Number of Participants With Dose Reductions or Delays-Part 1 BID

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Count of Participants)
Part 1: GSK525762 20 mg BID0
Part 1: GSK525762 30 mg BID3
Part 1: GSK525762 40 mg BID1

Number of Participants With Dose Reductions or Delays-Part 1 QD

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionParticipants (Count of Participants)
Part 1: GSK525762 2 mg QD0
Part 1: GSK525762 4 mg QD0
Part 1: GSK525762 8 mg QD0
Part 1: GSK525762 16 mg QD0
Part 1: GSK525762 30 mg QD0
Part 1: GSK525762 60 mg QD2
Part 1: GSK525762 80 mg QD8
Part 1: GSK525762 100 mg QD7

Number of Participants With Dose Reductions or Delays-Part 2

The number of participants who had any dose reductions or delays is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Count of Participants)
Participants With NMC7
Participants With SCLC4
Participants With CRPC11
Participants With TNBC6
Participants With ER+BC6
Participants With GIST4

Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD

PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionParticipants (Number)
Part 1: GSK525762 2 mg QD0
Part 1: GSK525762 4 mg QD0
Part 1: GSK525762 8 mg QD0
Part 1: GSK525762 16 mg QD0
Part 1: GSK525762 30 mg QD0
Part 1: GSK525762 60 mg QD0
Part 1: GSK525762 80 mg QD2
Part 1: GSK525762 100 mg QD1

Number of Participants With PSA50 Response Rate-Part 1 BID

PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Number)
Part 1: GSK525762 20 mg BID0
Part 1: GSK525762 30 mg BID0
Part 1: GSK525762 40 mg BID0

Number of Participants With PSA50 Response-Besylate Sub-study

PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionParticipants (Number)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes0

Number of Participants With PSA50 Response-Part 2

PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Number)
Participants With NMC0
Participants With SCLC0
Participants With CRPC0
Participants With TNBC0
Participants With ER+BC0
Participants With GIST0

Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionParticipants (Count of Participants)
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes0
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes0

Number of Participants Withdrawn Due to Toxicities-Part 1 BID

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Count of Participants)
Part 1: GSK525762 20 mg BID0
Part 1: GSK525762 30 mg BID2
Part 1: GSK525762 40 mg BID2

Number of Participants Withdrawn Due to Toxicities-Part 1 QD

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionParticipants (Count of Participants)
Part 1: GSK525762 2 mg QD0
Part 1: GSK525762 4 mg QD1
Part 1: GSK525762 8 mg QD0
Part 1: GSK525762 16 mg QD0
Part 1: GSK525762 30 mg QD0
Part 1: GSK525762 60 mg QD2
Part 1: GSK525762 80 mg QD7
Part 1: GSK525762 100 mg QD2

Number of Participants Withdrawn Due to Toxicities-Part 2

Number of participants withdrawn due to toxicities is presented. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionParticipants (Count of Participants)
Participants With NMC1
Participants With SCLC3
Participants With CRPC6
Participants With TNBC4
Participants With ER+BC6
Participants With GIST2

Overall Response Rate-Besylate Sub-study

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionPercentage of participants (Number)
All Participants in Besylate Substudy0

Overall Response Rate-Part 1 BID

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionPercentage of participants (Number)
Part 1: GSK525762 20 mg BID0
Part 1: GSK525762 30 mg BID0
Part 1: GSK525762 40 mg BID0

Overall Response Rate-Part 1 QD

Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionPercentage of participants (Number)
Part 1: GSK525762 2 mg QD0
Part 1: GSK525762 4 mg QD25
Part 1: GSK525762 8 mg QD0
Part 1: GSK525762 16 mg QD0
Part 1: GSK525762 30 mg QD0
Part 1: GSK525762 60 mg QD0
Part 1: GSK525762 80 mg QD3
Part 1: GSK525762 100 mg QD11

Overall Response Rate-Part 2

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionPercentage of participants (Number)
Participants With NMC8
Participants With SCLC0
Participants With CRPC4
Participants With TNBC0
Participants With ER+BC0
Participants With GIST0

Overall Survival-Besylate Sub-study

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionMonths (Median)
All Participants in Besylate Substudy6.3

Overall Survival-Part 1 BID

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionMonths (Median)
Part 1: GSK525762 20 mg BIDNA
Part 1: GSK525762 30 mg BID6.0
Part 1: GSK525762 40 mg BID13.3

Overall Survival-Part 1 QD

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionMonths (Median)
Part 1: GSK525762 2 mg QD0.6
Part 1: GSK525762 4 mg QD4.1
Part 1: GSK525762 8 mg QD2.2
Part 1: GSK525762 16 mg QD9.1
Part 1: GSK525762 30 mg QD3.8
Part 1: GSK525762 60 mg QD8.9
Part 1: GSK525762 80 mg QD7.1
Part 1: GSK525762 100 mg QD9.8

Overall Survival-Part 2

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionMonths (Median)
Participants With NMC5.0
Participants With SCLC2.6
Participants With CRPC9.1
Participants With TNBC5.0
Participants With ER+BC8.8
Participants With GIST7.3

Progression Free Survival-Besylate Sub-study

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

InterventionMonths (Median)
All Participants in Besylate Substudy3.5

Progression Free Survival-Part 1 BID

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionMonths (Median)
Part 1: GSK525762 20 mg BID7.7
Part 1: GSK525762 30 mg BID5.6
Part 1: GSK525762 40 mg BID8.0

Progression Free Survival-Part 1 QD

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

InterventionMonths (Median)
Part 1: GSK525762 2 mg QD0.3
Part 1: GSK525762 4 mg QD4.1
Part 1: GSK525762 8 mg QD2.2
Part 1: GSK525762 16 mg QD9.1
Part 1: GSK525762 30 mg QD3.8
Part 1: GSK525762 60 mg QD3.6
Part 1: GSK525762 80 mg QD6.5
Part 1: GSK525762 100 mg QD7.5

Progression Free Survival-Part 2

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

InterventionMonths (Median)
Participants With NMC4.8
Participants With SCLC2.2
Participants With CRPC8.0
Participants With TNBC2.4
Participants With ER+BC4.7
Participants With GIST3.4

Time to Reach Cmax (Tmax) for GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

InterventionHours (Median)
GSK525762 80 mg Amorphous+6 mg Stable Isotope0.5833
GSK525762 80 mg Besylate+6 mg Stable Isotope0.8083
GSK525762 30 mg Besylate+6 mg Stable Isotope0.8333
GSK525762 80 mg Besylate Fed2.0000

Apparent Clearance of GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionLiter per hour (Geometric Mean)
Week1 AM dose;n=3,10,5Week1 PM dose;n=4,7,5Week3 AM dose;n=3,7,3Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID23.24621.74516.73118.867
Part 1: GSK525762 30 mg BID9.62111.05711.94920.133
Part 1: GSK525762 40 mg BID14.15516.38234.62337.097

Apparent Clearance of GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionLiter per hour (Geometric Mean)
Week1;n=3,4,1,3,4,9,32,9Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD13.70726.188
Part 1: GSK525762 16 mg QD18.03623.823
Part 1: GSK525762 2 mg QD11.46713.082
Part 1: GSK525762 30 mg QD6.7209.535
Part 1: GSK525762 4 mg QD11.08511.955
Part 1: GSK525762 60 mg QD13.76923.296
Part 1: GSK525762 8 mg QD18.47024.277
Part 1: GSK525762 80 mg QD13.58927.029

Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0 to 24]); AUC From Time 0 to Last Quantifiable Concentration (AUC [0 to t]) and AUC Extrapolated to Infinity (AUC[0 to Inf]) of GSK525762-Besylate Sub-study

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy. (NCT01587703)
Timeframe: Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

,,,
InterventionHours*nanograms per milliliter (Geometric Mean)
AUC(0 to 24)AUC(0 to inf)AUC(0 to t)
GSK525762 30 mg Besylate+6 mg Stable Isotope2977.33096.93053.9
GSK525762 80 mg Amorphous+6 mg Stable Isotope6954.37292.07227.1
GSK525762 80 mg Besylate Fed9123.89727.79597.1
GSK525762 80 mg Besylate+6 mg Stable Isotope7377.97703.47657.6

AUC (0 to Inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionHours*nanogram per milliter (Geometric Mean)
AUC (0 to 24); Week1 AM dose;n=3,10,5AUC (0 to 24); Week1 PM dose;n=4,7,5AUC (0 to 24); Week3 AM dose;n=3,7,3AUC (0 to 24); Week3 PM dose;n=3,5,3AUC (0 to inf); Week1 AM dose;n=3,10,5AUC (0 to t); Week1 AM dose;n=4,10,5AUC (0 to t); Week1 PM dose;n=4,9,5AUC (0 to t); Week3 AM dose;n=3,7,3AUC (0 to t); Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID856.1981.41279.01155.8860.4932.2927.51194.61053.6
Part 1: GSK525762 30 mg BID3067.03261.12725.31662.13118.32727.22840.42472.41490.8
Part 1: GSK525762 40 mg BID2794.42607.61184.61131.62825.82579.02446.71140.91073.6

AUC (0 to t), AUC (0 to 24) and AUC (0 to Inf) of GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. PK parameter population comprised of all participants in the PK Concentration Population (all participants in the All Treated Population for whom a blood sample for pharmacokinetics is obtained and analyzed) for whom a PK parameter has been obtained. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionHours*nanogram per milliliter (Geometric Mean)
AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD6958.33818.57295.67218.43819.9
Part 1: GSK525762 16 mg QD867.9671.6887.1877.7672.3
Part 1: GSK525762 2 mg QD169.2152.9174.4168.6152.8
Part 1: GSK525762 30 mg QD3943.23146.24464.54147.83164.3
Part 1: GSK525762 4 mg QD354.3334.6360.8357.5334.3
Part 1: GSK525762 60 mg QD4225.02575.64357.54304.12576.9
Part 1: GSK525762 8 mg QD431.5329.5433.1431.1330.6
Part 1: GSK525762 80 mg QD5692.42959.85887.25667.32953.8

Lambda z for GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionPer hour (Geometric Mean)
Week1 AM dose;n=3,10,5Week1 PM dose;n=3,7,3Week3 AM dose;n=3,7,3Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID0.234630.211710.235650.20507
Part 1: GSK525762 30 mg BID0.199890.143070.217510.19263
Part 1: GSK525762 40 mg BID0.237210.187890.308680.29133

Lambda z for GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionPer hour (Geometric Mean)
Week1;n=3,4,1,3,4,9,32,9Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD0.109920.17560
Part 1: GSK525762 16 mg QD0.099030.15599
Part 1: GSK525762 2 mg QD0.214110.15579
Part 1: GSK525762 30 mg QD0.078630.12513
Part 1: GSK525762 4 mg QD0.135540.15472
Part 1: GSK525762 60 mg QD0.124680.17629
Part 1: GSK525762 8 mg QD0.231260.14087
Part 1: GSK525762 80 mg QD0.156130.16667

Maximum Observed Concentration for GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionNanogram per milliliter (Geometric Mean)
Week1;n=3,4,1,3,4,9,32,9Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD1080.49918.56
Part 1: GSK525762 16 mg QD179.45137.57
Part 1: GSK525762 2 mg QD50.9552.04
Part 1: GSK525762 30 mg QD603.92602.70
Part 1: GSK525762 4 mg QD70.4653.37
Part 1: GSK525762 60 mg QD889.52633.71
Part 1: GSK525762 8 mg QD120.35103.18
Part 1: GSK525762 80 mg QD1099.81815.40

Maximum Observed Concentration of GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionNanogram per milliter (Geometric Mean)
Week1 AM dose;n=4,10,5Week1 PM dose;n=4,9,5Week3 AM dose;n=3,7,3Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID231.68166.62284.71256.08
Part 1: GSK525762 30 mg BID628.01445.17604.38263.72
Part 1: GSK525762 40 mg BID703.31425.76419.15229.91

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. All Treated Population comprised of all participants who received at least one dose of study treatment. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
Any AEAny SAE
Part 1: GSK525762 100 mg QD93
Part 1: GSK525762 16 mg QD30
Part 1: GSK525762 2 mg QD30
Part 1: GSK525762 30 mg QD31
Part 1: GSK525762 4 mg QD42
Part 1: GSK525762 60 mg QD92
Part 1: GSK525762 8 mg QD10
Part 1: GSK525762 80 mg QD3121

Number of Participants With AEs and SAEs-Part 1 BID

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Any AEAny SAE
Part 1: GSK525762 20 mg BID40
Part 1: GSK525762 30 mg BID104
Part 1: GSK525762 40 mg BID52

Number of Participants With AEs and SAEs-Part 2

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Any AEAny SAE
Participants With CRPC2316
Participants With ER+BC2115
Participants With GIST138
Participants With NMC116
Participants With SCLC149
Participants With TNBC1911

Number of Participants With Changes in Blood Pressure From Baseline-Part 2

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
DBP; Increase to Grade 1;n=11,14,22,19,19,12DBP; Increase to Grade 2;n=11,14,22,19,19,12DBP; Increase to Grade 3/4;n=11,14,22,19,19,12SBP; Increase to Grade 1;n=11,14,21,19,19,12SBP; Increase to Grade 2;n=11,14,21,19,19,12SBP; Increase to Grade 3/4;n=11,14,21,19,19,12
Participants With CRPC8412113
Participants With ER+BC461741
Participants With GIST312170
Participants With NMC240420
Participants With SCLC310441
Participants With TNBC532931

Number of Participants With Changes in Pulse Rate From Baseline-Besylate Sub-study

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
Pulse rate; decrease to <60Pulse rate; Change to normal/no changePulse rate; increase to >100
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes032
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes014

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 BID

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Pulse rate; decrease to <60Pulse rate; Change to normal/no changePulse rate; increase to >100
Part 1: GSK525762 20 mg BID031
Part 1: GSK525762 30 mg BID046
Part 1: GSK525762 40 mg BID023

Number of Participants With Changes in Pulse Rate From Baseline-Part 1 QD

"Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Participants were counted twice if the participant Decreased to <60 and Increased to >100 post-baseline. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented" (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
Pulse rate; decrease to <60Pulse rate; Change to normal/no changePulse rate; increase to >100
Part 1: GSK525762 100 mg QD145
Part 1: GSK525762 16 mg QD111
Part 1: GSK525762 2 mg QD021
Part 1: GSK525762 30 mg QD013
Part 1: GSK525762 4 mg QD112
Part 1: GSK525762 60 mg QD152
Part 1: GSK525762 8 mg QD001
Part 1: GSK525762 80 mg QD11218

Number of Participants With Changes in Pulse Rate From Baseline-Part 2

"Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Participants were counted twice if the participant Decreased to <60 and Increased to >100 post-baseline." (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Pulse rate; decrease to <60Pulse rate; Change to normal/no changePulse rate; increase to >100
Participants With CRPC0139
Participants With ER+BC1910
Participants With GIST183
Participants With NMC075
Participants With SCLC1104
Participants With TNBC0119

Number of Participants With Changes in Temperature From Baseline-Besylate Sub-study

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
Decrease to <=35Change to normal/No changeIncrease to >=38
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes041
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes050

Number of Participants With Changes in Temperature From Baseline-Part 1 BID

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Decrease to <=35Change to normal/No changeIncrease to >=38
Part 1: GSK525762 20 mg BID040
Part 1: GSK525762 30 mg BID091
Part 1: GSK525762 40 mg BID050

Number of Participants With Changes in Temperature From Baseline-Part 1 QD

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
Decrease to <=35Change to normal/No changeIncrease to >=38
Part 1: GSK525762 100 mg QD180
Part 1: GSK525762 16 mg QD030
Part 1: GSK525762 2 mg QD030
Part 1: GSK525762 30 mg QD031
Part 1: GSK525762 4 mg QD031
Part 1: GSK525762 60 mg QD090
Part 1: GSK525762 8 mg QD010
Part 1: GSK525762 80 mg QD2273

Number of Participants With Changes in Temperature From Baseline-Part 2

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Decrease to <=35Change to normal/No changeIncrease to >=38
Participants With CRPC0202
Participants With ER+BC1181
Participants With GIST0120
Participants With NMC1100
Participants With SCLC0113
Participants With TNBC0181

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=5,5Glucose; Increase to Grade 3; n=5,5Glucose; Increase to Grade 4; n=5,5Albumin; Any grade increase; n=5,5Albumin; Increase to Grade 3; n=5,5Albumin; Increase to Grade 4; n=5,5ALP; Any grade increase; n=5,5ALP; Increase to Grade 3; n=5,5ALP; Increase to Grade 4; n=5,5ALT; Any grade increase; n=5,5ALT; Increase to Grade 3; n=5,5ALT; Increase to Grade 4; n=5,5Amylase; Any grade increase; n=5,5Amylase; Increase to Grade 3; n=5,5Amylase; Increase to Grade 4; n=5,5AST; Any grade increase; n=5,5AST; Increase to Grade 3; n=5,5AST; Increase to Grade 4; n=5,5Dir bil; Any grade increase; n=5,5Dir bil; Increase to Grade 3; n=5,5Dir bil; Increase to Grade 4; n=5,5Bilirubin; Any grade increase; n=5,5Bilirubin; Increase to Grade 3; n=5,5Bilirubin; Increase to Grade 4; n=5,5NT-BNP; Any grade increase; n=5,5NT-BNP; Increase to Grade 3; n=5,5NT-BNP; Increase to Grade 4; n=5,5Calcium; Any grade increase; n=5,5Calcium; Increase to Grade 3; n=5,5Calcium; Increase to Grade 4; n=5,5Cholesterol; Any grade increase; n=5,3Cholesterol; Increase to Grade 3; n=5,3Cholesterol; Increase to Grade 4; n=5,3CK; Any grade increase; n=5,5CK; Increase to Grade 3; n=5,5CK; Increase to Grade 4; n=5,5Chloride; Any grade increase; n=5,5Chloride; Increase to Grade 3; n=5,5Chloride; Increase to Grade 4; n=5,5CO2; Any grade increase; n=5,5CO2; Increase to Grade 3; n=5,5CO2; Increase to Grade 4; n=5,5Creatinine; Any grade increase; n=5,5Creatinine; Increase to Grade 3; n=5,5Creatinine; Increase to Grade 4; n=5,5GGT; Any grade increase; n=5,5GGT; Increase to Grade 3; n=5,5GGT; Increase to Grade 4; n=5,5HDL; Any grade increase; n=5,3HDL; Increase to Grade 3; n=5,3HDL; Increase to Grade 4; n=5,3Insulin; Any grade increase; n=5,5Insulin; Increase to Grade 3; n=5,5Insulin; Increase to Grade 4; n=5,5Potassium; Any grade increase; n=5,5Potassium; Increase to Grade 3; n=5,5Potassium; Increase to Grade 4; n=5,5LDL; Any grade increase; n=5,3LDL; Increase to Grade 3; n=5,3LDL; Increase to Grade 4; n=5,3Lipase; Any grade increase; n=5,4Lipase; Increase to Grade 3; n=5,4Lipase; Increase to Grade 4;n=5,4Magnesium; Any grade increase; n=5,5Magnesium; Increase to Grade 3; n=5,5Magnesium; Increase to Grade 4; n=5,5Protein; Any grade increase; n=5,5Protein; Increase to Grade 3; n=5,5Protein; Increase to Grade 4; n=5,5Sodium; Any grade increase; n=5,5Sodium; Increase to Grade 3; n=5,5Sodium; Increase to Grade 4; n=5,5Thyroxine; Any grade increase; n=5,3Thyroxine; Increase to Grade 3; n=5,3Thyroxine; Increase to Grade 4; n=5,3Testosterone; Any grade increase; n=2,1Testosterone; Increase to Grade 3; n=2,1Testosterone; Increase to Grade 4; n=2,1Triglycerides; Any grade increase; n=5,3Triglycerides; Increase to Grade 3; n=5,3Triglycerides; Increase to Grade 4; n=5,3Troponin T; Any grade increase; n=5,5Troponin T; Increase to Grade 3; n=5,5Troponin T; Increase to Grade 4; n=5,5Urate; Any grade increase; n=5,5Urate; Increase to Grade 3; n=5,5Urate; Increase to Grade 4; n=5,5Urea; Any grade increase; n=5,5Urea; Increase to Grade 3; n=5,5Urea; Increase to Grade 4; n=5,5
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes500300000100000100000420000200000000000000100000000000300000000110000310000000200000000000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Besylate Sub-study

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=5,5Glucose; Increase to Grade 3; n=5,5Glucose; Increase to Grade 4; n=5,5Albumin; Any grade increase; n=5,5Albumin; Increase to Grade 3; n=5,5Albumin; Increase to Grade 4; n=5,5ALP; Any grade increase; n=5,5ALP; Increase to Grade 3; n=5,5ALP; Increase to Grade 4; n=5,5ALT; Any grade increase; n=5,5ALT; Increase to Grade 3; n=5,5ALT; Increase to Grade 4; n=5,5Amylase; Any grade increase; n=5,5Amylase; Increase to Grade 3; n=5,5Amylase; Increase to Grade 4; n=5,5AST; Any grade increase; n=5,5AST; Increase to Grade 3; n=5,5AST; Increase to Grade 4; n=5,5Dir bil; Any grade increase; n=5,5Dir bil; Increase to Grade 3; n=5,5Dir bil; Increase to Grade 4; n=5,5Bilirubin; Any grade increase; n=5,5Bilirubin; Increase to Grade 3; n=5,5Bilirubin; Increase to Grade 4; n=5,5NT-BNP; Any grade increase; n=5,5NT-BNP; Increase to Grade 3; n=5,5NT-BNP; Increase to Grade 4; n=5,5Calcium; Any grade increase; n=5,5Calcium; Increase to Grade 3; n=5,5Calcium; Increase to Grade 4; n=5,5Cholesterol; Any grade increase; n=5,3Cholesterol; Increase to Grade 3; n=5,3Cholesterol; Increase to Grade 4; n=5,3CK; Any grade increase; n=5,5CK; Increase to Grade 3; n=5,5CK; Increase to Grade 4; n=5,5Chloride; Any grade increase; n=5,5Chloride; Increase to Grade 3; n=5,5Chloride; Increase to Grade 4; n=5,5CO2; Any grade increase; n=5,5CO2; Increase to Grade 3; n=5,5CO2; Increase to Grade 4; n=5,5Creatinine; Any grade increase; n=5,5Creatinine; Increase to Grade 3; n=5,5Creatinine; Increase to Grade 4; n=5,5GGT; Any grade increase; n=5,5GGT; Increase to Grade 3; n=5,5GGT; Increase to Grade 4; n=5,5HDL; Any grade increase; n=5,3HDL; Increase to Grade 3; n=5,3HDL; Increase to Grade 4; n=5,3Insulin; Any grade increase; n=5,5Insulin; Increase to Grade 3; n=5,5Insulin; Increase to Grade 4; n=5,5Potassium; Any grade increase; n=5,5Potassium; Increase to Grade 3; n=5,5Potassium; Increase to Grade 4; n=5,5LDL; Any grade increase; n=5,3LDL; Increase to Grade 3; n=5,3LDL; Increase to Grade 4; n=5,3Lipase; Any grade increase; n=5,4Lipase; Increase to Grade 3; n=5,4Lipase; Increase to Grade 4;n=5,4Magnesium; Any grade increase; n=5,5Magnesium; Increase to Grade 3; n=5,5Magnesium; Increase to Grade 4; n=5,5Protein; Any grade increase; n=5,5Protein; Increase to Grade 3; n=5,5Protein; Increase to Grade 4; n=5,5Sodium; Any grade increase; n=5,5Sodium; Increase to Grade 3; n=5,5Sodium; Increase to Grade 4; n=5,5Thyroxine; Any grade increase; n=5,3Thyroxine; Increase to Grade 3; n=5,3Thyroxine; Increase to Grade 4; n=5,3Testosterone; Any grade increase; n=2,1Testosterone; Increase to Grade 3; n=2,1Testosterone; Increase to Grade 4; n=2,1Triglycerides; Any grade increase; n=5,3Triglycerides; Increase to Grade 3; n=5,3Triglycerides; Increase to Grade 4; n=5,3Troponin I; Any grade increase; n=1,0Troponin I; Increase to Grade 3; n=1,0Troponin I; Increase to Grade 4; n=1,0Troponin T; Any grade increase; n=5,5Troponin T; Increase to Grade 3; n=5,5Troponin T; Increase to Grade 4; n=5,5Urate; Any grade increase; n=5,5Urate; Increase to Grade 3; n=5,5Urate; Increase to Grade 4; n=5,5Urea; Any grade increase; n=5,5Urea; Increase to Grade 3; n=5,5Urea; Increase to Grade 4; n=5,5
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes400310100100000200000310000100100200000000100000000000300000000200000200000000100000000000000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 BID

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=4, 10, 5Glucose; Increase to Grade 3; n=4, 10, 5Glucose; Increase to Grade 4; n=4, 10, 5Albumin; Any grade increase; n=4, 10, 5Albumin; Increase to Grade 3; n=4, 10, 5Albumin; Increase to Grade 4; n=4, 10, 5ALP; Any grade increase; n=4, 10, 5ALP; Increase to Grade 3; n=4, 10, 5ALP; Increase to Grade 4; n=4, 10, 5ALT; Any grade increase; n=4, 10, 5ALT; Increase to Grade 3; n=4, 10, 5ALT; Increase to Grade 4; n=4, 10, 5Amylase; Any grade increase; n=4, 10, 5Amylase; Increase to Grade 3; n=4, 10, 5Amylase; Increase to Grade 4; n=4, 10, 5AST; Any grade increase; n=4, 10, 5AST; Increase to Grade 3; n=4, 10, 5AST; Increase to Grade 4; n=4, 10, 5Dir bil; Any grade increase; n=4, 9, 4Dir bil; Increase to Grade 3; n=4, 9, 4Dir bil; Increase to Grade 4; n=4, 9, 4Bilirubin; Any grade increase; n=4, 10, 5Bilirubin; Increase to Grade 3; n=4, 10, 5Bilirubin; Increase to Grade 4; n=4, 10, 5NT-BNP; Any grade increase; n=4, 10, 5NT-BNP; Increase to Grade 3; n=4, 10, 5NT-BNP; Increase to Grade 4; n=4, 10, 5Calcium; Any grade increase; n=4, 10, 5Calcium; Increase to Grade 3; n=4, 10, 5Calcium; Increase to Grade 4; n=4, 10, 5Cholesterol; Any grade increase; n=2, 9, 5Cholesterol; Increase to Grade 3; n=2, 9, 5Cholesterol; Increase to Grade 4; n=2, 9, 5CK; Any grade increase; n=4, 10, 5CK; Increase to Grade 3; n=n=4, 10, 5CK; Increase to Grade 4; n=n=4, 10, 5Chloride; Any grade increase; n=4, 10, 5Chloride; Increase to Grade 3; n=4, 10, 5Chloride; Increase to Grade 4; n=4, 10, 5CO2; Any grade increase; n=4, 10, 5CO2; Increase to Grade 3; n=4, 10, 5CO2; Increase to Grade 4; n=4, 10, 5Creatinine; Any grade increase; n=4, 10, 5Creatinine; Increase to Grade 3; n=4, 10, 5Creatinine; Increase to Grade 4; n=4, 10, 5GGT; Any grade increase; n=4, 10, 5GGT; Increase to Grade 3; n=4, 10, 5GGT; Increase to Grade 4; n=4, 10, 5HDL; Any grade increase; n=2, 9, 5HDL; Increase to Grade 3; n=2, 9, 5HDL; Increase to Grade 4; n=2, 9, 5Insulin; Any grade increase; n=4, 10, 5Insulin; Increase to Grade 3; n=4, 10, 5Insulin; Increase to Grade 4; n=4, 10, 5Potassium; Any grade increase; n=4, 10, 5Potassium; Increase to Grade 3; n=4, 10, 5Potassium; Increase to Grade 4; n=4, 10, 5LDL; Any grade increase; n=2, 9, 5LDL; Increase to Grade 3; n=2, 9, 5LDL; Increase to Grade 4; n=2, 9, 5Lipase; Any grade increase; n=4, 10, 5Lipase; Increase to Grade 3; n=4, 10, 5Lipase; Increase to Grade 4; n=4, 10, 5Magnesium; Any grade increase; n=4, 10, 5Magnesium; Increase to Grade 3; n=4, 10, 5Magnesium; Increase to Grade 4; n=4, 10, 5Protein; Any grade increase; n=4, 10, 5Protein; Increase to Grade 3; n=4, 10, 5Protein; Increase to Grade 4; n=4, 10, 5Sodium; Any grade increase; n=4, 10, 5Sodium; Increase to Grade 3; n=4, 10, 5Sodium; Increase to Grade 4; n=4, 10, 5Thyroxine; Any grade increase; n=3, 9, 5Thyroxine; Increase to Grade 3; n=3, 9, 5Thyroxine; Increase to Grade 4; n=3, 9, 5Testosterone; Any grade increase; n=1, 4, 4Testosterone; Increase to Grade 3; n=1, 4, 4Testosterone; Increase to Grade 4; n=1, 4, 4Triglycerides; Any grade increase; n=2, 9, 5Triglycerides; Increase to Grade 3; n=2, 9, 5Triglycerides; Increase to Grade 4; n=2, 9, 5Troponin I; Any grade increase; n=3, 10, 5Troponin I; Increase to Grade 3; n=3, 10, 5Troponin I; Increase to Grade 4; n=3, 10, 5Troponin T; Any grade increase; n=4, 10, 5Troponin T; Increase to Grade 3; n=4, 10, 5Troponin T; Increase to Grade 4; n=4, 10, 5Urate; Any grade increase; n=4, 10, 5Urate; Increase to Grade 3; n=4, 10, 5Urate; Increase to Grade 4; n=4, 10, 5Urea; Any grade increase; n=4, 10, 5Urea; Increase to Grade 3; n=4, 10, 5Urea; Increase to Grade 4; n=4, 10, 5
Part 1: GSK525762 20 mg BID110000000000000200000110000100000000000000000000000000100000000000000000000000000000000000000
Part 1: GSK525762 30 mg BID930400420510200620000711000200200300000000200411000000500000210201000720000000400000000000000
Part 1: GSK525762 40 mg BID510100200100200100000210000100000200000000200100000000200000300200000200000000400000000000000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9Albumin; Any grade increase; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9ALP; Any grade increase; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9ALT; Any grade increase; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9Amylase; Any grade increase; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9AST; Any grade increase; n=2,4,1,3,4,9,32,9AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9Calcium; Any grade increase; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9CK;Any grade increase;n=3,4,1,3,4,9,31,9CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9Chloride; Any grade increase; n=2,4,1,3,4,9,32,9Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9Insulin; Any grade increase; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9Potassium;Any grade increase;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8Lipase;Any grade increase; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9Protein;Any grade increase; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9Sodium;Any grade increase; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9Urate;Any grade increase; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9Urea; Any grade increase; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 16 mg QD300000000000100000000000000100000000000000000000000000300000000100000100000000000000000
Part 1: GSK525762 4 mg QD200200000000101100000000000100000100000000000100000000200000000200000301000200000000000
Part 1: GSK525762 8 mg QD100000000100000100000100000000000000000000000000000000000000000100000000000000000000000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9Albumin; Any grade increase; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9ALP; Any grade increase; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9ALT; Any grade increase; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9Amylase; Any grade increase; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9AST; Any grade increase; n=2,4,1,3,4,9,32,9AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9Calcium; Any grade increase; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9CK;Any grade increase;n=3,4,1,3,4,9,31,9CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9Chloride; Any grade increase; n=2,4,1,3,4,9,32,9Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9Insulin; Any grade increase; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9Potassium;Any grade increase;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8Lipase;Any grade increase; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9Protein;Any grade increase; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9Sodium;Any grade increase; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9Urate;Any grade increase; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9Urea; Any grade increase; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 2 mg QD000000000000100200000000000110000000000000000000000000200000101000000100000000000000101000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9Albumin; Any grade increase; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9ALP; Any grade increase; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9ALT; Any grade increase; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9Amylase; Any grade increase; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9AST; Any grade increase; n=2,4,1,3,4,9,32,9AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9Calcium; Any grade increase; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9CK;Any grade increase;n=3,4,1,3,4,9,31,9CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9Chloride; Any grade increase; n=2,4,1,3,4,9,32,9Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9Insulin; Any grade increase; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9Potassium;Any grade increase;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8Lipase;Any grade increase; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9Protein;Any grade increase; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9Sodium;Any grade increase; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9Urate;Any grade increase; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9Urea; Any grade increase; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 100 mg QD830100000200110310000810000300100500000000300100000000310000200200000400000000601000000000000
Part 1: GSK525762 30 mg QD200100100100200200000110000200000100000000100100000000000000000100000210000000200000000101000
Part 1: GSK525762 80 mg QD242012007109001011140000015500001700110011200000007101121000000131100083090000016400000001700000000101000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1 QD

Blood samples were collected for the analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading was done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 3; n=2,4,1,3,4,9,32,9Glucose; Increase to Grade 4; n=2,4,1,3,4,9,32,9Albumin; Any grade increase; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Albumin; Increase to Grade 4; n=2,4,1,3,4,9,32,9ALP; Any grade increase; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 3; n=2,4,1,3,4,9,31,9ALP; Increase to Grade 4; n=2,4,1,3,4,9,31,9ALT; Any grade increase; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 3; n=2,4,1,3,4,9,32,9ALT; Increase to Grade 4; n=2,4,1,3,4,9,32,9Amylase; Any grade increase; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 3; n=2,4,1,3,4,9,32,9Amylase; Increase to Grade 4; n=2,4,1,3,4,9,32,9AST; Any grade increase; n=2,4,1,3,4,9,32,9AST; Increase to Grade 3; n=2,4,1,3,4,9,32,9AST; Increase to Grade 4; n=2,4,1,3,4,9,32,9Dir bil; Any grade increase; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 3; n=2,4,1,3,4,9,30,9Dir bil; Increase to Grade 4; n=2,4,1,3,4,9,30,9Bilirubin; Any grade increase; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 3; n=2,4,1,3,4,9,32,9Bilirubin; Increase to Grade 4; n=2,4,1,3,4,9,32,9NT-BNP; Any grade increase; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 3; n=2,4,1,3,4,9,30,9NT-BNP; Increase to Grade 4; n=2,4,1,3,4,9,30,9Calcium; Any grade increase; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 3; n=2,4,1,3,4,9,32,9Calcium; Increase to Grade 4; n=2,4,1,3,4,9,32,9Cholesterol;Any grade increase;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 3;n=2,4,1,3,4,7,29,9Cholesterol;Increase to Grade 4;n=2,4,1,3,4,7,29,9CK;Any grade increase;n=3,4,1,3,4,9,31,9CK; Increase to Grade 3; n=3, 4, 1, 3, 4, 9, 31, 9CK; Increase to Grade 4; n=3, 4, 1, 3, 4, 9, 31, 9Chloride; Any grade increase; n=2,4,1,3,4,9,32,9Chloride; Increase to Grade 3;n=2,4,1,3,4,9,32,9Chloride;Increase to Grade 4;n=2,4,1,3,4,9,32,9CO2; Any grade increase; n=2, 4, 1, 3, 4, 9, 32, 9CO2; Increase to Grade 3; n=2,4,1,3,4,9,32,9CO2; Increase to Grade 4; n=2,4,1,3,4,9,32,9Creatinine;Any grade increase;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 3;n=2,4,1,3,4,9,32,9Creatinine;Increase to Grade 4;n=2,4,1,3,4,9,32,9GGT; Any grade increase; n=2, 4, 1, 3, 4, 9, 31, 7GGT;Increase to Grade 3; n=2,4,1,3,4,9,31,7GGT; Increase to Grade 4; n=2,4,1,3,4,9,31,7HDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 9HDL; Increase to Grade 3; n=2,4,1,3,4,7,28,9HDL; Increase to Grade 4; n=2,4,1,3,4,7,28,9Insulin; Any grade increase; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 3; n=2,4,1,3,4,9,31,9Insulin; Increase to Grade 4; n=2,4,1,3,4,9,31,9Potassium;Any grade increase;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Potassium;Increase to Grade 4;n=3,4,1,3,4,9,32,9LDH; Any grade increase; n=0, 0, 0, 0, 0, 1, 0, 0LDH; Increase to Grade 3; n=0, 0, 0, 0, 0, 1, 0, 0LDH; Increase to Grade 4; n=0, 0, 0, 0, 0, 1, 0, 0LDL; Any grade increase; n=2, 4, 1, 3, 4, 7, 28, 8LDL;Increase to Grade 3; n=2,4,1,3,4,7,28,8LDL;Increase to Grade 4; n=2,4,1,3,4,7,28,8Lipase;Any grade increase; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 3; n=2,4,1,3,4,9,31,9Lipase;Increase to Grade 4; n=2,4,1,3,4,9,31,9Magnesium;Any grade increase;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 3;n=3,4,1,3,4,9,32,9Magnesium;Increase to Grade 4;n=3,4,1,3,4,9,32,9Protein;Any grade increase; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 3; n=2,4,1,3,4,9,32,9Protein;Increase to Grade 4; n=2,4,1,3,4,9,32,9Sodium;Any grade increase; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 3; n=3,4,1,3,4,9,32,9Sodium;Increase to Grade 4; n=3,4,1,3,4,9,32,9Thyroxine;Any grade increase;n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 3; n=2,4,1,3,4,7,29,9Thyroxine;Increase to Grade 4; n=2,4,1,3,4,7,29,9Testosterone;Any grade increase;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade3;n=1,0,0,0,3,3,14,7Testosterone;Increase to Grade4;n=1,0,0,0,3,3,14,7Triglyc;Any grade increase;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 3;n=2,4,1,3,4,7,29,9Triglyc;Increase to Grade 4;n=2,4,1,3,4,7,29,9Troponin I;Any grade increase;n=0,0,0,0, 2,5,24,5Troponin I;Increase to Grade 3;n=0,0,0,0,2,5,24,5Troponin I;Increase to Grade 4; n=0,0,0,0,2,5,24,5Troponin T;Any grade increase;n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 3; n=3,4,1,3,4,9,31,9Troponin T;Increase to Grade 4; n=3,4,1,3,4,9,31,9Urate;Any grade increase; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 3; n=2,4,1,3,4,9,32,9Urate; Increase to Grade 4; n=2,4,1,3,4,9,32,9Urea; Any grade increase; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 3; n=2,4,1,3,4,9,31,9Urea; Increase to Grade 4; n=2,4,1,3,4,9,31,9
Part 1: GSK525762 60 mg QD700300000100000100000100000100000000000000000000000000200000000000000000300000000200000000000000

Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides (triglyc), troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Glucose; Any grade increase; n=11,13,23,19,21,12Glucose; Increase to Grade 3; n=11,13,23,19,21,12Glucose; Increase to Grade 4; n=11,13,23,19,21,12Albumin; Any grade increase; n=11,13,23,19,21,12Albumin; Increase to Grade 3; n=11,13,23,19,21,12Albumin; Increase to Grade 4; n=11,13,23,19,21,12ALP; Any grade increase; n=11,13,23,19,21,12ALP; Increase to Grade 3; n=11,13,23,19,21,12ALP; Increase to Grade 4; n=11,13,23,19,21,12ALT; Any grade increase; n=11,14,23,19,21,12ALT; Increase to Grade 3; n=11,14,23,19,21,12ALT; Increase to Grade 4; n=11,14,23,19,21,12Amylase; Any grade increase; n=11,12,22,19,20,12Amylase; Increase to Grade 3; n=11,12,22,19,20,12Amylase; Increase to Grade 4; n=11,12,22,19,20,12AST; Any grade increase; n=11,13,23,19,21,12AST; Increase to Grade 3; n=11,13,23,19,21,12AST; Increase to Grade 4; n=11,13,23,19,21,12Dir bil; Any grade increase; n=11,13,23,19,20,12Dir bil; Increase to Grade 3; n=11,13,23,19,20,12Dir bil; Increase to Grade 4; n=11,13,23,19,20,12Bilirubin;Any grade increase;n=11,14,23,19,21,12Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12NT-BNP; Any grade increase; n=11,12,22,17,15,12NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12Calcium; Any grade increase; n=11,13,23,19,21,12Calcium; Increase to Grade 3; n=11,13,23,19,21,12Calcium; Increase to Grade 4; n=11,13,23,19,21,12Cholesterol;Any grade increase;n=10,12,22,19,20,12Cholesterol;Increase to Grade3;n=10,12,22,19,20,12Cholesterol;Increase to Grade4;n=10,12,22,19,20,12CK; Any grade increase; n=9,9,21,17,18,11CK; Increase to Grade 3; n=9,9,21,17,18,11CK; Increase to Grade 4; n=9,9,21,17,18,11Chloride; Any grade increase; n=11,13,23,19,21,12Chloride; Increase to Grade 3; n=11,13,23,19,21,12Chloride; Increase to Grade 4; n=11,13,23,19,21,12CO2; Any grade increase; n=11,12,23,19,21,12CO2; Increase to Grade 3; n=11,12,23,19,21,12CO2; Increase to Grade 4; n=11,12,23,19,21,12Creatinine;Any grade increase;n=11,14,23,19,21,12Creatinine;Increase to Grade3;n=11,14,23,19,21,12Creatinine;Increase to Grade4;n=11,14,23,19,21,12GGT; Any grade increase; n=11,13,22,19,20,12GGT; Increase to Grade 3; n=11,13,22,19,20,12GGT; Increase to Grade 4; n=11,13,22,19,20,12HDL; Any grade increase; n=10,10,22,19,19,12HDL; Increase to Grade 3; n=10,10,22,19,19,12HDL; Increase to Grade 4;n=10,10,22,19,19,12Insulin; Any grade increase; n=11,12,22,19,20,12Insulin; Increase to Grade 3; n=11,12,22,19,20,12Insulin; Increase to Grade 4; n=11,12,22,19,20,12Potassium; Any grade increase; n=11,14,23,19,21,12Potassium;Increase to Grade3;n=11,14,23,19,21,12Potassium;Increase to Grade4;n=11,14,23,19,21,12LDL; Any grade increase; n=10,10,22,19,19,12LDL; Increase to Grade 3; n=10,10,22,19,19,12LDL; Increase to Grade 4;n=10,10,22,19,19,12Lipase; Any grade increase; n=11,12,22,19,20,12Lipase; Increase to Grade 3;n=11,12,22,19,20,12Lipase; Increase to Grade 4;n=11,12,22,19,20,12Magnesium; Any grade increase; n=11,12,22,19,21,12Magnesium; Increase to Grade 3;n=11,12,22,19,21,12Magnesium; Increase to Grade4;n=11,12,22,19,21,12Protein; Any grade increase; n=11,13,23,19,21,12Protein; Increase to Grade 3;n=11,13,23,19,21,12Protein; Increase to Grade 4;n=11,13,23,19,21,12Sodium; Any grade increase; n=11, 14,23,19,21,12Sodium; Increase to Grade 3; n=11, 14,23,19,21,12Sodium; Increase to Grade 4; n=11, 14,23,19,21,12Thyroxine; Any grade increase;n=7,7,20,15,18,8Thyroxine; Increase to Grade3;n=7,7,20,15,18,8Thyroxine; Increase to Grade4;n=7,7,20,15,18,8Testosterone; Any grade increase; n=4,3,18,0,1,5Testosterone; Increase to Grade3; n=4,3,18,0,1,5Testosterone; Increase to Grade4; n=4,3,18,0,1,5Triglyc;Any grade increase;n=10,12,22,19,20,12Triglyc;Increase to Grade3;n=10,12,22,19,20,12Triglyc;Increase to Grade4;n=10,12,22,19,20,12Troponin I; Any grade increase; n=7,6,15,15,14,7Troponin I; Increase to Grade 3; n=7,6,15,15,14,7Troponin I; Increase to Grade 4; n=7,6,15,15,14,7Troponin T;Any grade increase;n=11,12,22,19,20,12Troponin T;Increase to Grade3;n=11,12,22,19,20,12Troponin T;Increase to Grade4;n=11,12,22,19,20,12Urate; Any grade increase; n=11,12,22,19,20,12Urate; Increase to Grade 3; n=11,12,22,19,20,12Urate; Increase to Grade 4; n=11,12,22,19,20,12Urea; Any grade increase; n=11,14,23,17,17,11Urea; Increase to Grade 3; n=11,14,23,17,17,11Urea; Increase to Grade 4;n=11,14,23,17,17,11
Part 2: Participants With CRPC20009006206009201010000132000082020040000000092172000000010100007005000008100000001540000000202000
Part 2: Participants With ER+BC18107104001200620143000013300003109007000000006006310000007000004014000004000000001110000000000000
Part 2: Participants With GIST920500400300100600000400000300500500000000300100000000710000200100000520000000800000000202000
Part 2: Participants With NMC1000500300300510300000810000610500300000000300000000000600000320200000501000000710000000000000
Part 2: Participants With SCLC10006001006105205000001010000300200200000000400300000000400000530200000510000000700000000000000
Part 2: Participants With TNBC16008003005005208100006000004002000000000002005200000005000005111000005200000001000000000000000

Number of Participants With Grade Change From Baseline in Hematology Data-Besylate Sub-study

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
Basophils; Any grade increaseBasophils; Increase to Grade 3Basophils; Increase to Grade 4Eosinophils; Any grade increaseEosinophils; Increase to Grade 3Eosinophils; Increase to Grade 4Hemoglobin; Any grade increaseHemoglobin; Increase to Grade 3Hemoglobin; Increase to Grade 4INR; Any grade increaseINR; Increase to Grade 3INR; Increase to Grade 4Lymphocytes; Any grade increaseLymphocytes; Increase to Grade 3Lymphocytes; Increase to Grade 4Monocytes; Any grade increaseMonocytes; Increase to Grade 3Monocytes; Increase to Grade 4Neutrophils; Any grade increaseNeutrophils; Increase to Grade 3Neutrophils; Increase to Grade 4Platelets; Any grade increasePlatelets; Increase to Grade 3Platelets; Increase to Grade 4PT; Any grade increasePT; Increase to Grade 3PT; Increase to Grade 4RBC; Any grade increaseRBC; Increase to Grade 3RBC; Increase to Grade 4WBC; Any grade increaseWBC; Increase to Grade 3WBC; Increase to Grade 4Fib; Any grade increaseFib; Increase to Grade 3Fib; Increase to Grade 4aPTT; Any grade increaseaPTT; Increase to Grade 3aPTT; Increase to Grade 4
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes000000420100312000100503000000300000400
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes000000320100400000100521000000100000200

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 BID

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Basophils; Any grade increase; n=4,10,5Basophils; Increase to Grade 3; n=4,10,5Basophils; Increase to Grade 4; n=4,10,5Eosinophils; Any grade increase; n=4,10,5Eosinophils; Increase to Grade3; n=4,10,5Eosinophils; Increase to Grade4; n=4,10,5Hemoglobin; Any grade increase; n=4,10,5Hemoglobin; Increase to Grade 3; n=4,10,5Hemoglobin; Increase to Grade 4; n=4,10,5INR; Any grade increase; n=4,10,5INR; Increase to Grade 3; n=4,10,5INR; Increase to Grade 4; n=4,10,5Lymphocytes; Any grade increase; n=4,10,5Lymphocytes; Increase to Grade3; n=4,10,5Lymphocytes; Increase to Grade4; n=4,10,5Monocytes; Any grade increase; n=4,10,5Monocytes;Increase to Grade3; n=4,10,5Monocytes; Increase to Grade 4; n=4,10,5Neutrophils; Any grade increase; n=4,10,5Neutrophils; Increase to Grade 3; n=4,10,5Neutrophils; Increase to Grade 4; n=4,10,5Platelets; Any grade increase; n=4,10,5Platelets; Increase to Grade 3; n=4,10,5Platelets; Increase to Grade 4; n=4,10,5PT; Any grade increase;n=4,10,5PT; Increase to Grade 3; n=4,10,5PT; Increase to Grade 4; n=4,10,5RBC; Any grade increase; n=4,10,5RBC; Increase to Grade 3; n=4,10,5RBC; Increase to Grade 4; n=4,10,5WBC; Any grade increase; n=4,10,5WBC; Increase to Grade 3; n=4,10,5WBC; Increase to Grade 4; n=4,10,5Fib; Any grade increase; n=4,10,5Fib; Increase to Grade 3; n=4,10,5Fib; Increase to Grade 4; n=4,10,5aPTT; Any grade increase; n=4,10,5aPTT; Increase to Grade 3; n=4,10,5aPTT; Increase to Grade 4; n=4,10,5
Part 1: GSK525762 20 mg BID000000400000200000000100000000100000000
Part 1: GSK525762 30 mg BID0000008306008400000001020000000000000500
Part 1: GSK525762 40 mg BID000000420300200000100521000000100000200

Number of Participants With Grade Change From Baseline in Hematology Data-Part 1 QD

Blood samples were collected for the analysis of hematology parameters: activated partial thromboplastin time (aPTT), platelet count, red blood cell count (RBC), white blood cell count (WBC), prothrombin international normalized ratio (INR), prothrombin time (PT), fibrinogen (Fib), hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
Basophils;Any grade increaseBasophils;Increase to Grade 3Basophils;Increase to Grade 4Eosinophils;Any grade increaseEosinophils;Increase to Grade3Eosinophils;Increase to Grade 4Hemoglobin;Any grade increaseHemoglobin;Increase to Grade 3; n=2,4,1,3,4,9,32,9Hemoglobin;Increase to Grade 4INR; Any grade increaseINR;Increase to Grade 3INR; Increase to Grade 4Lymphocytes;Any grade increaseLymphocytes;Increase to Grade3Lymphocytes;Increase to Grade4Monocytes;Any grade increaseMonocytes;Increase to Grade3Monocytes;Increase to Grade 4Neutrophils;Any grade increaseNeutrophils;Increase to Grade 3Neutrophils;Increase to Grade 4Platelets;Any grade increasePlatelets;Increase to Grade 3Platelets;Increase to Grade 4PT; Any grade increasePT; Increase to Grade 3PT; Increase to Grade 4RBC; Any grade increaseRBC;Increase to Grade 3RBC;Increase to Grade 4WBC; Any grade increaseWBC; Increase to Grade 3WBC; Increase to Grade 4Fib; Any grade increaseFib;Increase to Grade 3Fib;Increase to Grade 4aPTT; Any grade increaseaPTT; Increase to Grade 3aPTT; Increase to Grade 4
Part 1: GSK525762 100 mg QD000000710200411000310852000000510000200
Part 1: GSK525762 16 mg QD000000200000000000000000000000000000000
Part 1: GSK525762 2 mg QD000000100200100000000000000000000000000
Part 1: GSK525762 30 mg QD000000210000200000000200000000000000000
Part 1: GSK525762 4 mg QD000000100200210000000110000000100000000
Part 1: GSK525762 60 mg QD0000002101005200000000501000000300000000
Part 1: GSK525762 8 mg QD000000000100100000000000000000000000000
Part 1: GSK525762 80 mg QD0000002190210019810007012611500000011014001410

Number of Participants With Grade Change From Baseline in Hematology Data-Part 2

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Basophils; Any grade increase; n=11,13,23,19,21,13Basophils; Increase to Grade3; n=11,13,23,19,21,13Basophils; Increase to Grade4; n=11,13,23,19,21,13Eosinophils;Any grade increase;n=11,13,23,19,21,13Eosinophils;Increase to Grade3;n=11,13,23,19,21,13Eosinophils;Increase to Grade4;n=11,13,23,19,21,13Hemoglobin;Any grade increase;n=11,14,23,19,21,13Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13INR; Any grade increase; n=11,12,21,17,18,12INR; Increase to Grade3; n=11,12,21,17,18,12INR; Increase to Grade4; n=11,12,21,17,18,12Lymphocytes;Any grade increase;n=11,13,23,19,21,13Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13Monocytes; Any grade increase; n=11,13,23,19,21,13Monocytes;Increase to Grade3; n=11,13,23,19,21,13Monocytes; Increase to Grade4; n=11,13,23,19,21,13Neutrophils;Any grade increase;n=11,14,23,19,21,13Neutrophils;Increase to Grade3;n=11,14,23,19,21,13Neutrophils;Increase to Grade4;n=11,14,23,19,21,13Platelets; Any grade increase; n=11,14,23,19,21,13Platelets; Increase to Grade3; n=11,14,23,19,21,13Platelets; Increase to Grade4; n=11,14,23,19,21,13PT; Any grade increase;n=10,10, 18, 17, 18, 12PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12RBC; Any grade increase; n=11, 13, 23, 19, 21, 13RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13WBC; Any grade increase; n=11, 14, 23, 19, 21, 13WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13Fib; Any grade increase; n=11, 11, 21, 17, 18, 12Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12aPTT; Any grade increase; n=11,12,21,17,18,12aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12aPTT; Increase to Grade4; n=11,12,21,17,18,12
Participants With CRPC00000018901300146000008002058000000910100100
Participants With ER+BC0000001850110013100006101862000000600000500
Participants With GIST000000630700600000100700000000300100400
Participants With NMC000000630800820000410742000000710210400
Participants With SCLC00000010206007210004101243000000500000400
Participants With TNBC00000010408009200003201764000000510000310

Number of Participants With Increase in Blood Pressure From Baseline-Besylate Sub-study

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
DBP; Increase to Grade 1DBP; Increase to Grade 2DBP; Increase to Grade 3/4SBP; Increase to Grade 1SBP; Increase to Grade 2SBP; Increase to Grade 3/4
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes120100
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes110110

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 BID

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
DBP; Increase to Grade 1;n=4,10,4DBP; Increase to Grade 2;n=4,10,4DBP; Increase to Grade 3/4;n=4,10,4SBP; Increase to Grade 1;n=4,9,5SBP; Increase to Grade 2;n=4,9,5SBP; Increase to Grade 3/4;n=4,9,5
Part 1: GSK525762 20 mg BID200110
Part 1: GSK525762 30 mg BID440260
Part 1: GSK525762 40 mg BID111211

Number of Participants With Increase in Blood Pressure From Baseline-Part 1 QD

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
DBP; Increase to Grade 1DBP; Increase to Grade 2DBP; Increase to Grade 3/4SBP; Increase to Grade 1SBP; Increase to Grade 2SBP; Increase to Grade 3/4
Part 1: GSK525762 100 mg QD012132
Part 1: GSK525762 16 mg QD010110
Part 1: GSK525762 2 mg QD200110
Part 1: GSK525762 30 mg QD010130
Part 1: GSK525762 4 mg QD100101
Part 1: GSK525762 60 mg QD301212
Part 1: GSK525762 8 mg QD010100
Part 1: GSK525762 80 mg QD91021195

Number of Participants With Increase in QT Interval Corrected for Heart Rate According to Fridericia's Formula (QTcF)-Part 1 QD

Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.38 months of drug exposure

,,,,,,,
InterventionParticipants (Count of Participants)
Any Grade increaseIncrease to Grade 2Increase to Grade 3
Part 1: GSK525762 100 mg QD410
Part 1: GSK525762 16 mg QD100
Part 1: GSK525762 2 mg QD101
Part 1: GSK525762 30 mg QD400
Part 1: GSK525762 4 mg QD000
Part 1: GSK525762 60 mg QD410
Part 1: GSK525762 8 mg QD000
Part 1: GSK525762 80 mg QD1300

Number of Participants With Increase in QTcF-Besylate Sub-study

ECG measurements were done using 12-lead ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QTcF intervals. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
Any Grade increaseIncrease to Grade 2Increase to Grade 3
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes200
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes000

Number of Participants With Increase in QTcF-Part 1 BID

ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

,,
InterventionParticipants (Count of Participants)
Any Grade increaseIncrease to Grade 2Increase to Grade 3
Part 1: GSK525762 20 mg BID330
Part 1: GSK525762 30 mg BID400
Part 1: GSK525762 40 mg BID200

Number of Participants With Increase in QTcF-Part 2

ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. (NCT01587703)
Timeframe: Median of 1.41 months of drug exposure

,,,,,
InterventionParticipants (Count of Participants)
Any Grade increaseIncrease to Grade 2Increase to Grade 3
Participants With CRPC600
Participants With ER+BC220
Participants With GIST000
Participants With NMC101
Participants With SCLC200
Participants With TNBC100

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression

InterventionParticipants (Count of Participants)
Glucose; Week 5;n=2,7,3Glucose; Week 9;n=0,4,2Glucose; disc/prog;n=0,6,1Ketones; Week 5;n=2,7,3Occult blood; Week 5;n=2,7,3Occult blood; Week 9;n=0,4,2Occult blood; disc/prog;n=0,6,1pH; Week 5;n=2,7,3pH; Week 9;n=0,4,2pH; disc/prog;n=0,7,1Protein; Week 5;n=2,7,3Protein; Week 9;n=0,4,2Protein; disc/prog;n=0,7,1Erythrocytes; Week 5;n=1,5,1Erythrocytes; Week 9;n=0,1,1Specific gravity; Week 5;n=2,7,3Specific gravity; Week 9;n=0,4,2Specific gravity; disc/prog;n=0,7,1Leukocytes; Week 5;n=1,5,1Leukocytes; Week 9;n=0,1,1
Part 1: GSK525762 40 mg BID10000002111011121011

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression

InterventionParticipants (Count of Participants)
Glucose; Week 5;n=2,7,3Glucose; Week 9;n=0,4,2Glucose; Week 17;n=0,2,0Glucose; disc/prog;n=0,6,1Ketones; Week 5;n=2,7,3Ketones; Week 17;n=0,2,0Occult blood; Week 5;n=2,7,3Occult blood; Week 9;n=0,4,2Occult blood; disc/prog;n=0,6,1pH; Week 5;n=2,7,3pH; Week 9;n=0,4,2pH; Week 17;n=0,2,0pH; disc/prog;n=0,7,1Protein; Week 5;n=2,7,3Protein; Week 9;n=0,4,2Protein; Week 17;n=0,2,0Protein; disc/prog;n=0,7,1Erythrocytes; Week 5;n=1,5,1Erythrocytes; Week 9;n=0,1,1Erythrocytes; Week 17;n=0,1,0Specific gravity; Week 5;n=2,7,3Specific gravity; Week 9;n=0,4,2Specific gravity; Week 17;n=0,2,0Specific gravity; disc/prog;n=0,7,1Leukocytes; Week 5;n=1,5,1Leukocytes; Week 9;n=0,1,1Leukocytes; Week 17;n=0,1,0
Part 1: GSK525762 30 mg BID011111212441432214011112401

Number of Participants With Maximum Urinalysis Change From Baseline Data-Part 1 BID

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression

InterventionParticipants (Count of Participants)
Glucose; Week 5;n=2,7,3Ketones; Week 5;n=2,7,3Occult blood; Week 5;n=2,7,3pH; Week 5;n=2,7,3Protein; Week 5;n=2,7,3Erythrocytes; Week 5;n=1,5,1Specific gravity; Week 5;n=2,7,3Leukocytes; Week 5;n=1,5,1
Part 1: GSK525762 20 mg BID00020120

Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,17,25 and disc/prog

InterventionParticipants (Count of Participants)
Hyaline casts; Week5;n=1,1Hyaline casts; Week9;n=2,1Glucose; Week5;n=3,2Glucose; Week9;n=4,1Ketones; Week9;n=4,1pH;Week5;n=3,2pH;Week9;n=4,1pH;disc/prog;n=2,2Protein; Week5; n=3,2Protein; Week9; n=4,1Erythrocytes; Week9; n=4,1Specific gravity; Week5; n=3,2Specific gravity; Week9; n=4,1Specific gravity; disc/prog; n=2,2Leukocytes; Week5; n=3,1Leukocytes; Week9; n=4,1
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes1010010111110111

Number of Participants With Maximum Urinalysis Change From Baseline-Besylate Sub-study

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,17,25 and disc/prog

InterventionParticipants (Count of Participants)
Hyaline casts; Week5;n=1,1Hyaline casts; Week9;n=2,1Hyaline casts; Week17;n=1,0Hyaline casts; Week25;n=1,0Glucose; Week5;n=3,2Glucose; Week9;n=4,1Glucose; Week17;n=2,0Ketones; Week9;n=4,1pH;Week5;n=3,2pH;Week9;n=4,1pH;Week17;n=2,0pH;Week25;n=1,0pH;disc/prog;n=2,2Protein; Week5; n=3,2Protein; Week9; n=4,1Protein; Week17; n=2,0Protein; Week25; n=1,0Erythrocytes; Week9; n=4,1Erythrocytes; Week17; n=2,0Erythrocytes; Week25; n=1,0Erythrocytes; disc/prog; n=1,0Specific gravity; Week5; n=3,2Specific gravity; Week9; n=4,1Specific gravity; Week17; n=2,0Specific gravity; Week25; n=1,0Specific gravity; disc/prog; n=2,2Leukocytes; Week5; n=3,1Leukocytes; Week9; n=4,1Leukocytes; Week17; n=2,0Leukocytes; Week25; n=1,0Leukocytes; disc/prog; n=1,0
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes1111111133212332121111211034111

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Occult blood;Week 5; n=1,2,1,3,2,7,17,7pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1Protein;Week 5; n=1, 2,1,3,2,7,20,7Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Leukocytes;Week 5; n=1,2,1,2,2,6,11,6
Part 1: GSK525762 8 mg QD0000000000

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4
Part 1: GSK525762 30 mg QD000002000002011

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4
Part 1: GSK525762 2 mg QD0000000000001100

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1pH;Disc/Prog; n=0,1,0,1,0,3,17,2Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Protein;Disc/Prog; n=0,1,0,1,0,3,17,2Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 16 mg QD001001001100000201000

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Disc/Prog; n=0,1,0,1,0,3,17,2Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Protein;Disc/Prog; n=0,1,0,1,0,3,17,2Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 60 mg QD000000000000521310521200

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Week 25; n=0,1,0,0,0,0,3,1Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5Occult blood;Week 17; n=0, 1,0,0,0,0,5,3Occult blood;Week 25; n=0,1,0,0,0,0,3,1Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1pH;Disc/Prog; n=0,1,0,1,0,3,17,2Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Protein;Week 17; n=0,1,0,0,0,0,5,3Protein;Week 25; n=0,1,0,0,0,0,3,1Protein;Disc/Prog; n=0,1,0,1,0,3,17,2Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Week 17; n=0,1,0,0,0,0,5,3Specific gravity;Week 25; n=0,1,0,0,0,0,3,1Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4Leukocytes;Week 17; n=0,1,0,0,0,0,1,2Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 100 mg QD101121101000000321143001542012101

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Week 25; n=0,1,0,0,0,0,3,1Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5Occult blood;Week 17; n=0, 1,0,0,0,0,5,3Occult blood;Week 25; n=0,1,0,0,0,0,3,1Occult blood;Week 33; n=0,1,0,0,0,0,2,0Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1pH;Week 33; n=0,1,0,0,0,0,2,0pH;Disc/Prog; n=0,1,0,1,0,3,17,2Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Protein;Week 17; n=0,1,0,0,0,0,5,3Protein;Week 25; n=0,1,0,0,0,0,3,1Protein;Disc/Prog; n=0,1,0,1,0,3,17,2Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Week 17; n=0,1,0,0,0,0,5,3Specific gravity;Week 25; n=0,1,0,0,0,0,3,1Specific gravity;Week 33; n=0,1,0,0,0,0,2,0Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4Leukocytes;Week 17; n=0,1,0,0,0,0,1,2Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 4 mg QD0000000000000001111010001011110000

Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

InterventionParticipants (Count of Participants)
Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1Cellular casts; Week 17; n=0,0, 0, 0, 0,0,1,0Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3Glucose;Week 5; n=1,2,1,3,2,7,20,7Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5Glucose;Week 25; n=0,1,0,0,0,0,3,1Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2Ketones;Week 5; n=1,2,1,3,2,7,20,7Ketones;Week 9; n=1,1,0,1,1,3,12,5Occult blood;Week 5; n=1,2,1,3,2,7,17,7Occult blood;Week 9; n=1,1,0,1,1,3,11,5Occult blood;Week 17; n=0, 1,0,0,0,0,5,3Occult blood;Week 25; n=0,1,0,0,0,0,3,1Occult blood;Week 33; n=0,1,0,0,0,0,2,0Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2pH;Week 5; n=1, 2, 1, 3,2,7,20,7pH;Week 9; n=1,1,0,1,1,3,12,5pH;Week 25; n=0,1,0,0,0,0,3,1pH;Week 33; n=0,1,0,0,0,0,2,0pH;Disc/Prog; n=0,1,0,1,0,3,17,2Protein;Week 5; n=1, 2,1,3,2,7,20,7Protein;Week 9; n=1,1,0,1,1,3,12,5Protein;Week 17; n=0,1,0,0,0,0,5,3Protein;Week 25; n=0,1,0,0,0,0,3,1Protein;Disc/Prog; n=0,1,0,1,0,3,17,2Specific gravity;Week 5; n=1,2,1,3,2,7,20,7Specific gravity;Week 9; n=1,1,0,1,1,3,12,5Specific gravity;Week 17; n=0,1,0,0,0,0,5,3Specific gravity;Week 25; n=0,1,0,0,0,0,3,1Specific gravity;Week 33; n=0,1,0,0,0,0,2,0Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2Specific gravity;Week 41; n=0,0,0,0,0,0,1,0Specific gravity;Week 49; n=0,0,0,0,0,0,1,0Leukocytes;Week 5; n=1,2,1,2,2,6,11,6Leukocytes;Week 9; n=1,1,0,1,1,1,6,4Leukocytes;Week 17; n=0,1,0,0,0,0,1,2Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Part 1: GSK525762 80 mg QD111204101222311126810997115764116114314

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

InterventionParticipants (Count of Participants)
Granular cast;disc/prog;n=1,2,6,3,4,0Hyaline cast;Week9;n=0,0,1,2,1,1Glucose;Week 5;n=8,7,18,12,14,8Glucose;Week9;n=8,3,12,3,6,5Glucose;Week13;n=7,2,6,1,2,2Glucose;disc/prog;n=3,6,16,12,12,5Ketones;Week5;n=8,7,18,12,14,8Ketones;Week9;n=8,3,12,3,6,5Ketones;disc/prog;n=3,6,16,12,12,5Occult blood;Week5;n=8,7,18,12,14,8Occult blood;Week9;n=8,3,12,3,6,5Occult blood;Week13;n=7,2,6,1,2,2Occult blood;disc/prog;n=3,6,16,12,12,5pH;Week5;n=8,7,18,12,14,8pH;Week9;n=8,3,12,3,6,5pH;Week13;n=7,2,6,1,2,2pH;disc/prog;n=3,6,16,12,12,5Protein;Week5;n=8,7,18,12,14,8Protein;Week9;n=8,3,12,3,6,5Protein;Week13;n=7,2,6,1,2,2Protein;disc/prog;n=3,6,16,12,12,5Erythrocytes;Week5;n=3,3,8,4,4,4Erythrocytes;Week9;n=4,0,2,2,1,2Erythrocytes;Week13;n=3,1,0,0,0,1Erythrocytes;disc/prog;n=1,2,6,3,4,2Specific gravity;Week5;n=8,7,18,12,14,8Specific gravity;Week9;n=8,3,12,3,6,5Specific gravity;Week13;n=7,2,6,1,2,2Specific gravity;disc/prog;n=3,6,16,12,12,5Leukocytes;Week5;n=3,3,8,4,4,4Leukocytes;Week9;n=4,0,2,2,1,3Leukocytes;Week13;n=3,1,0,0,0,1Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With GIST011000000000032126302210023114301

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

InterventionParticipants (Count of Participants)
Granular cast;Week5;n=0,2,2,1,3,0Granular cast;disc/prog;n=1,2,6,3,4,0Hyaline cast;Week5;n=1,2,2,2,4,0Hyaline cast;Week13;n=1,1,0,0,0,0Hyaline cast;disc/prog;n=1,2,6,3,4,0Glucose;Week 5;n=8,7,18,12,14,8Glucose;Week9;n=8,3,12,3,6,5Glucose;Week13;n=7,2,6,1,2,2Glucose;disc/prog;n=3,6,16,12,12,5Ketones;Week5;n=8,7,18,12,14,8Ketones;Week9;n=8,3,12,3,6,5Ketones;disc/prog;n=3,6,16,12,12,5Occult blood;Week5;n=8,7,18,12,14,8Occult blood;Week9;n=8,3,12,3,6,5Occult blood;Week13;n=7,2,6,1,2,2Occult blood;disc/prog;n=3,6,16,12,12,5pH;Week5;n=8,7,18,12,14,8pH;Week9;n=8,3,12,3,6,5pH;Week13;n=7,2,6,1,2,2pH;disc/prog;n=3,6,16,12,12,5Protein;Week5;n=8,7,18,12,14,8Protein;Week9;n=8,3,12,3,6,5Protein;Week13;n=7,2,6,1,2,2Protein;disc/prog;n=3,6,16,12,12,5Erythrocytes;Week5;n=3,3,8,4,4,4Erythrocytes;Week13;n=3,1,0,0,0,1Erythrocytes;disc/prog;n=1,2,6,3,4,2Specific gravity;Week5;n=8,7,18,12,14,8Specific gravity;Week9;n=8,3,12,3,6,5Specific gravity;Week13;n=7,2,6,1,2,2Specific gravity;disc/prog;n=3,6,16,12,12,5Leukocytes;Week5;n=3,3,8,4,4,4Leukocytes;Week13;n=3,1,0,0,0,1Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With SCLC0001021101110100311212110104112101

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

,
InterventionParticipants (Count of Participants)
Granular cast;Week5;n=0,2,2,1,3,0Granular cast;disc/prog;n=1,2,6,3,4,0Hyaline cast;Week5;n=1,2,2,2,4,0Hyaline cast;Week9;n=0,0,1,2,1,1Hyaline cast;disc/prog;n=1,2,6,3,4,0Glucose;Week 5;n=8,7,18,12,14,8Glucose;Week9;n=8,3,12,3,6,5Glucose;Week13;n=7,2,6,1,2,2Glucose;disc/prog;n=3,6,16,12,12,5Ketones;Week5;n=8,7,18,12,14,8Ketones;Week9;n=8,3,12,3,6,5Ketones;disc/prog;n=3,6,16,12,12,5Occult blood;Week5;n=8,7,18,12,14,8Occult blood;Week9;n=8,3,12,3,6,5Occult blood;Week13;n=7,2,6,1,2,2Occult blood;disc/prog;n=3,6,16,12,12,5pH;Week5;n=8,7,18,12,14,8pH;Week9;n=8,3,12,3,6,5pH;Week13;n=7,2,6,1,2,2pH;disc/prog;n=3,6,16,12,12,5Protein;Week5;n=8,7,18,12,14,8Protein;Week9;n=8,3,12,3,6,5Protein;Week13;n=7,2,6,1,2,2Protein;disc/prog;n=3,6,16,12,12,5Erythrocytes;Week5;n=3,3,8,4,4,4Erythrocytes;Week9;n=4,0,2,2,1,2Erythrocytes;disc/prog;n=1,2,6,3,4,2Specific gravity;Week5;n=8,7,18,12,14,8Specific gravity;Week9;n=8,3,12,3,6,5Specific gravity;Week13;n=7,2,6,1,2,2Specific gravity;disc/prog;n=3,6,16,12,12,5Leukocytes;Week5;n=3,3,8,4,4,4Leukocytes;Week9;n=4,0,2,2,1,3Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With ER+BC1010000011010000640550033127505403
Part 2: Participants With TNBC0010000000000000321630022115203313

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

InterventionParticipants (Count of Participants)
Granular cast;Week5;n=0,2,2,1,3,0Granular cast;disc/prog;n=1,2,6,3,4,0Hyaline cast;Week5;n=1,2,2,2,4,0Hyaline cast;Week9;n=0,0,1,2,1,1Hyaline cast;disc/prog;n=1,2,6,3,4,0Glucose;Week 5;n=8,7,18,12,14,8Glucose;Week9;n=8,3,12,3,6,5Glucose;Week13;n=7,2,6,1,2,2Glucose;Week37;n=3,0,1,0,0,0Glucose;Week49;n=1,0,1,0,0,0Glucose;disc/prog;n=3,6,16,12,12,5Ketones;Week5;n=8,7,18,12,14,8Ketones;Week9;n=8,3,12,3,6,5Ketones;disc/prog;n=3,6,16,12,12,5Occult blood;Week5;n=8,7,18,12,14,8Occult blood;Week9;n=8,3,12,3,6,5Occult blood;Week13;n=7,2,6,1,2,2Occult blood;Week25;n=2,0,3,0,0,0Occult blood;Week37;n=3,0,1,0,0,0Occult blood;disc/prog;n=3,6,16,12,12,5pH;Week5;n=8,7,18,12,14,8pH;Week9;n=8,3,12,3,6,5pH;Week13;n=7,2,6,1,2,2pH;Week25;n=2,0,3,0,0,0pH;Week37;n=3,0,1,0,0,0pH;Week49;n=1,0,1,0,0,0pH;disc/prog;n=3,6,16,12,12,5Protein;Week5;n=8,7,18,12,14,8Protein;Week9;n=8,3,12,3,6,5Protein;Week13;n=7,2,6,1,2,2Protein;Week37;n=1,0,1,0,0,0Protein;disc/prog;n=3,6,16,12,12,5Erythrocytes;Week5;n=3,3,8,4,4,4Erythrocytes;Week9;n=4,0,2,2,1,2Erythrocytes;disc/prog;n=1,2,6,3,4,2Specific gravity;Week5;n=8,7,18,12,14,8Specific gravity;Week9;n=8,3,12,3,6,5Specific gravity;Week13;n=7,2,6,1,2,2Specific gravity;disc/prog;n=3,6,16,12,12,5Leukocytes;Week5;n=3,3,8,4,4,4Leukocytes;Week9;n=4,0,2,2,1,3Leukocytes;Week25;n=2,0,1,0,0,0Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With CRPC0200220100000255010887310069420651522135212

Number of Participants With Maximum Urinalysis Change From Baseline-Part 2

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. (NCT01587703)
Timeframe: Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

InterventionParticipants (Count of Participants)
Granular cast;disc/prog;n=1,2,6,3,4,0Hyaline cast;Week5;n=1,2,2,2,4,0Hyaline cast;Week13;n=1,1,0,0,0,0Hyaline cast;disc/prog;n=1,2,6,3,4,0Glucose;Week 5;n=8,7,18,12,14,8Glucose;Week9;n=8,3,12,3,6,5Glucose;Week13;n=7,2,6,1,2,2Glucose;Week37;n=3,0,1,0,0,0Glucose;Week49;n=1,0,1,0,0,0Glucose;Week73;n=1,0,0,0,0,0Glucose;Week85;n=1,0,0,0,0,0Glucose;disc/prog;n=3,6,16,12,12,5Ketones;Week5;n=8,7,18,12,14,8Ketones;Week9;n=8,3,12,3,6,5Ketones;disc/prog;n=3,6,16,12,12,5Occult blood;Week5;n=8,7,18,12,14,8Occult blood;Week9;n=8,3,12,3,6,5Occult blood;Week13;n=7,2,6,1,2,2Occult blood;Week25;n=2,0,3,0,0,0Occult blood;Week37;n=3,0,1,0,0,0Occult blood;disc/prog;n=3,6,16,12,12,5pH;Week5;n=8,7,18,12,14,8pH;Week9;n=8,3,12,3,6,5pH;Week13;n=7,2,6,1,2,2pH;Week25;n=2,0,3,0,0,0pH;Week37;n=3,0,1,0,0,0pH;Week49;n=1,0,1,0,0,0pH;Week73;n=1,0,0,0,0,0pH;Week85;n=1,0,0,0,0,0pH;disc/prog;n=3,6,16,12,12,5Protein;Week5;n=8,7,18,12,14,8Protein;Week9;n=8,3,12,3,6,5Protein;Week13;n=7,2,6,1,2,2Protein;Week37;n=1,0,1,0,0,0Protein;disc/prog;n=3,6,16,12,12,5Erythrocytes;Week5;n=3,3,8,4,4,4Erythrocytes;Week9;n=4,0,2,2,1,2Erythrocytes;Week13;n=3,1,0,0,0,1Erythrocytes;disc/prog;n=1,2,6,3,4,2Specific gravity;Week5;n=8,7,18,12,14,8Specific gravity;Week9;n=8,3,12,3,6,5Specific gravity;Week13;n=7,2,6,1,2,2Specific gravity;disc/prog;n=3,6,16,12,12,5Leukocytes;Week5;n=3,3,8,4,4,4Leukocytes;Week9;n=4,0,2,2,1,3Leukocytes;Week13;n=3,1,0,0,0,1Leukocytes;Week25;n=2,0,1,0,0,0Leukocytes;disc/prog;n=1,2,7,3,4,1
Part 2: Participants With NMC010012211110000101010652131111133112230422010100

Number of Participants With Non-serious AEs and SAEs-Besylate Sub-study

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment (NCT01587703)
Timeframe: Median of 1.87 months of drug exposure

,
InterventionParticipants (Count of Participants)
Any non-serious AEAny SAE
80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes53
80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes53

Tmax for GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionHour (Median)
Week1 AM dose;n=4,10,5Week1 PM dose;n=4,9,5Week3 AM dose;n=3,7,3Week3 PM dose;n=3,6,3
Part 1: GSK525762 20 mg BID1.55001.95831.18331.0000
Part 1: GSK525762 30 mg BID0.96671.96671.06671.4500
Part 1: GSK525762 40 mg BID0.55001.98330.58332.0667

Tmax for GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionHours (Median)
Week1;n=3,4,1,3,4,9,32,9Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD1.00001.5000
Part 1: GSK525762 16 mg QD2.01671.0500
Part 1: GSK525762 2 mg QD0.58331.0000
Part 1: GSK525762 30 mg QD2.00830.9000
Part 1: GSK525762 4 mg QD1.22502.5083
Part 1: GSK525762 60 mg QD1.00001.0583
Part 1: GSK525762 8 mg QD1.10000.5000
Part 1: GSK525762 80 mg QD1.00000.5667

Volume of Distribution of GSK525762-Part 1 BID

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

,,
InterventionLiters (Geometric Mean)
Week1 AM dose;n=3,10,5Week1 PM dose;n=3,7,3Week3 AM dose;n=3,7,3Week3 PM dose;n=3,5,3
Part 1: GSK525762 20 mg BID99.07116.5271.0092.00
Part 1: GSK525762 30 mg BID48.1377.2854.94104.52
Part 1: GSK525762 40 mg BID59.6781.11112.17127.34

Volume of Distribution of GSK525762-Part 1 QD

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. (NCT01587703)
Timeframe: pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

,,,,,,,
InterventionLiters (Geometric Mean)
Week1;n=3,4,1,3,4,9,32,9Week3;n=1,2,1,3,4,6,16,6
Part 1: GSK525762 100 mg QD124.70149.14
Part 1: GSK525762 16 mg QD182.13152.72
Part 1: GSK525762 2 mg QD53.5683.97
Part 1: GSK525762 30 mg QD85.4676.20
Part 1: GSK525762 4 mg QD81.7977.27
Part 1: GSK525762 60 mg QD110.44132.14
Part 1: GSK525762 8 mg QD79.87172.33
Part 1: GSK525762 80 mg QD87.03162.17

Number of Participants With Pathologic Complete Remission (pCR)

Histopathologic assessment of surgical resection to confirm Pathologoic Complete Remission. Complete remission defined as disappearance of all target lesions. (NCT00512096)
Timeframe: restaging with second and fourth 21-day cycles followed by surgery

Interventionparticipants (Number)
Cisplatin + Ifosfamide + Paclitaxel3

Reviews

11 reviews available for ifosfamide and Carcinoma, Epidermoid

ArticleYear
Ifosfamide in the treatment of head and neck cancer.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

2003
[Clinical features of patients with metastasis in phalanges as first symptom of primary lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcino

2007
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.
    Cancer treatment reviews, 1983, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm

1983
New agents in non-small cell lung cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti

1984
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study.
    Gynecologic oncology, 1994, Volume: 54, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq

1994
Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials

1995
Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment.
    Medical and pediatric oncology, 1996, Volume: 26, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytoge

1996
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2000
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl

2000
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
    Seminars in oncology, 2000, Volume: 27, Issue:4 Suppl 8

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Nec

2000
Neoadjuvant therapy for cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1992

Trials

68 trials available for ifosfamide and Carcinoma, Epidermoid

ArticleYear
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
    BMC cancer, 2017, Jun-28, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc

2017
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
    The Laryngoscope, 2008, Volume: 118, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2008
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell ce
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv

2009
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
    Anticancer research, 2009, Volume: 29, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control

2009
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2010
Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
    Gynecologic oncology, 2011, Volume: 120, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2011
A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

2011
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino

2012
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Cancer, 2002, Jul-15, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2002
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell;

2003
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2003
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
    British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2003
Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-01, Volume: 21, Issue:21

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2003
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino

2004
[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
    Akusherstvo i ginekologiia, 2003, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemothe

2003
Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer.
    The Tohoku journal of experimental medicine, 2004, Volume: 204, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci

2004
Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study.
    International journal of radiation oncology, biology, physics, 2005, Mar-01, Volume: 61, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell

2005
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Por
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di

2005
[Neoadjuvant chemotherapy with intra-arterial infusion in the treatment of advanced cervical cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch

2005
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Urology, 2007, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop

2007
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
    Investigational new drugs, 2008, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2008
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio

2008
Single-dose ifosfamide: efficacy studies in non-small cell lung cancer.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cl

1982
Use and safety of high-dose ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc

1982
Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future.
    Cancer treatment reviews, 1983, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sm

1983
New agents in non-small cell lung cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti

1984
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combina

1983
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin

1995
Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa

1994
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study.
    Gynecologic oncology, 1994, Volume: 54, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq

1994
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1995, Volume: 171, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc

1995
Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial.
    Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

1995
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
    Gynecologic oncology, 1995, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1995
A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1994, Volume: 6, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea

1994
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1993
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell

1993
Ifosfamide in advanced epidermoid head and neck cancer.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:4

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Hea

1993
Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
    American journal of obstetrics and gynecology, 1993, Volume: 168, Issue:3 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Ifosfamide; Mesna; Middle

1993
Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:2 Suppl 5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti

1996
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.
    American journal of clinical oncology, 1996, Volume: 19, Issue:4

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; H

1996
Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Lung cancer (Amsterdam, Netherlands), 1995, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell;

1995
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    The Journal of infusional chemotherapy, 1996,Winter, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che

1996
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

1996
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ca

1997
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    The Journal of urology, 1997, Volume: 158, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A

1997
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carci

1997
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr

1997
Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female;

1998
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc

1998
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

1998
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:3

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al

1998
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

1998
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
    American journal of clinical oncology, 1999, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl

1999
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
    Lung cancer (Amsterdam, Netherlands), 1998, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Ca

1998
Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy.
    Lung cancer (Amsterdam, Netherlands), 2000, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2000
Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix.
    American journal of clinical oncology, 2000, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

2000
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Cancer, 2001, Apr-01, Volume: 91, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2001
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
    Cancer, 2001, Aug-15, Volume: 92, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

2001
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine

2002
Protection against chemotherapy toxicity by IV hyperalimentation.
    Cancer treatment reports, 1978, Volume: 62, Issue:8

    Topics: Bacterial Vaccines; Carcinoma, Squamous Cell; Doxorubicin; Evaluation Studies as Topic; Humans; Ifos

1978
Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
    Cancer treatment reports, 1978, Volume: 62, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Bacterial Vaccines; Body Weight; Carcinoma, Squamous Cell; Clinical Tri

1978
Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo

1992
Neoadjuvant therapy for cervical cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1992
Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
    Oncology, 1991, Volume: 48, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head

1991
Gynecologic Oncology Group experience with ifosfamide.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy;

1990
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
    Cancer, 1990, Jun-15, Volume: 65, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1990
The role of ifosfamide in cervical cancer.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1989

Other Studies

98 other studies available for ifosfamide and Carcinoma, Epidermoid

ArticleYear
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Squamous Cell; Cisplatin;

2021
Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018, Volume: 28, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2018
Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis.
    BMC cancer, 2019, Jun-25, Volume: 19, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2019
Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer.
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2013, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2013
Robotic radical hysterectomy following neoadjuvant chemotherapy in FIGO stage IIIB cervical cancer: a case report.
    The international journal of medical robotics + computer assisted surgery : MRCAS, 2014, Volume: 10, Issue:1

    Topics: Adult; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; If

2014
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb

2013
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2013, Dec-18, Volume: 45, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou

2013
NUT midline carcinoma: an aggressive intrathoracic neoplasm.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Etoposid

2013
Neoadjuvant chemotherapy followed by robotic radical hysterectomy in locally advanced cervical cancer: a multi-institution study.
    Gynecologic oncology, 2014, Volume: 133, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2014
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab;

2015
Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer.
    Gynecologic oncology, 2014, Volume: 135, Issue:2

    Topics: Abortion, Spontaneous; Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Proto

2014
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell

2015
[Dramatic response of penile cancer with inguinal lymph node metastases to neoadjuvant chemotherapy with paclitaxel, ifosfamide and cisplatin : a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2015, Volume: 61, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci

2015
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
    Journal of gynecologic oncology, 2015, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
    Gynecologic oncology, 2015, Volume: 139, Issue:3

    Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin

2015
Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    The International journal of biological markers, 2015, Jul-22, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brac

2015
Feasibility of robotic radical hysterectomy after neoadjuvant chemotherapy in women with locally advanced cervical cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2016
Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2008
Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che

2008
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-20, Volume: 27, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2009
A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2009
Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy.
    Clinical breast cancer, 2009, Volume: 9, Issue:3

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modalit

2009
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control

2009
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
    Journal of surgical oncology, 2011, Volume: 104, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq

2011
Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risks and lymph-vascular space involvement.
    Chinese journal of cancer, 2011, Volume: 30, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati

2011
The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent.
    Oral oncology, 2012, Volume: 48, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cisplat

2012
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 117, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

2012
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
    Journal of radiation research, 2012, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2012
The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
    European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 163, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiother

2012
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.
    Gynecologic oncology, 2012, Volume: 126, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squ

2012
Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamo

2012
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2013
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Cancer, 2003, Mar-15, Volume: 97, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Tria

2003
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
    Neurology, 2003, Nov-11, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Si

2003
Long-lasting complete remission of a patient with cervical cancer FIGO IVB treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation chemotherapy--a case report.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin;

2004
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp

2005
Sarcomas of the head and neck. Results from the treatment of 25 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2005
[A case of thymic carcinoma responding to combination chemotherapy with nedaplatin, etoposide, and ifosfamide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration

2005
Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient.
    Gynecologic oncology, 2005, Volume: 98, Issue:2

    Topics: Carcinoma, Squamous Cell; Fanconi Syndrome; Female; Humans; Ifosfamide; Middle Aged; Osteomalacia; U

2005
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
    Revue des maladies respiratoires, 2005, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin

2005
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
    Gynecologic oncology, 2007, Volume: 105, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-

2007
Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2008
[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin].
    Deutsche medizinische Wochenschrift (1946), 1984, Jul-06, Volume: 109, Issue:27

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; C

1984
Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.
    Veterinary and human toxicology, 1981, Volume: 23, Issue:Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Administration, Oral; Carcinoma; Carcinoma, Small Cell; Carcinoma, S

1981
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati

1982
[Efficacy of sequential chemotherapy including vincristine, cisplatin and ifosfamide in the treatment of stage IV head and neck carcinomas and melanomas with visceral involvement. Preliminary results].
    Bulletin du cancer, 1984, Volume: 71, Issue:2

    Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou

1984
Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder.
    Cancer treatment reports, 1984, Volume: 68, Issue:2

    Topics: Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Fluoroura

1984
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose

1983
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela

1983
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
    Deutsche medizinische Wochenschrift (1946), 1983, May-27, Volume: 108, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos

1983
[Clinical studies of ifosfamide for gynecological malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I

1983
Serum zinc levels in lung cancer patients.
    Cancer, 1981, Apr-01, Volume: 47, Issue:7

    Topics: Adult; Aged; Bacterial Vaccines; Carcinoma, Squamous Cell; Copper; Doxorubicin; Humans; Ifosfamide;

1981
Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix.
    Indian journal of cancer, 1993, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1993
Methylene blue for ifosfamide-associated encephalopathy.
    The New England journal of medicine, 1995, May-04, Volume: 332, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carcinoma, Squamous Cell; Cisp

1995
[Epileptic seizures and treatment with ifosfamide-mesna].
    Revue neurologique, 1994, Volume: 150, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Epilepsy; Fatal Outcome; H

1994
Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma.
    Histopathology, 1994, Volume: 25, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

1994
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
    Journal of clinical pathology, 1993, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1993
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
    Journal of clinical pathology, 1995, Volume: 48, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr

1995
Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.
    Journal of clinical pathology, 1997, Volume: 50, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe

1997
Combined effects of ionizing radiation and 4-hydroperoxyfosfamide in vitro.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 46, Issue:3

    Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality T

1998
[Neoadjuvant chemotherapy for advanced cervical cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

1999
[Effect of combined carboplatin and ifosfamide with local hyperthermia on human mouth carcinoma in the animal model].
    Mund-, Kiefer- und Gesichtschirurgie : MKG, 1999, Volume: 3 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Comb

1999
Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival.
    International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dise

2001
A preclinical model for experimental chemotherapy of human head and neck cancer.
    International journal of oncology, 2001, Volume: 18, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin;

2001
[The value of qualitative regression grading as a prognostic factor for survival after preoperative radiochemotherapy in patients with advanced head and neck cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv

2001
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
    Cancer, 1978, Volume: 41, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos

1978
Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1992, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

1992
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin

1992
[Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer].
    Nihon Sanka Fujinka Gakkai zasshi, 1992, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents;

1992
[Elderly non-Hodgkin's lymphoma presenting with pulmonary squamous cell carcinoma as a complication of chemotherapy for malignant lymphoma].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1992, Volume: 29, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; Hu

1992
The potential for adjuvant therapy in early-stage cervical cancer.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B

1990
Chemotherapy in recurrent and advanced cervical cancer.
    Gynecologic oncology, 1991, Volume: 40, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati

1991
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
    Gynecologic oncology, 1991, Volume: 43, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Drug Therapy, Combination; Female; Hematolog

1991
[Cisplatin, ifosfamide and vindesine in the chemotherapy of squamous cell carcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Cisplatin; Dr

1991
Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Ifo

1990
[Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung

1990
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:5

    Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sma

1990
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr

1990
Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical uterine squamous-cell carcinoma.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

1990
A phase II study of ifosfamide in endometrial cancer.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;

1990
Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix.
    Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

1989
Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity.
    American journal of clinical oncology, 1989, Volume: 12, Issue:3

    Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Esophageal Neoplasms; Femal

1989
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
    Investigational new drugs, 1989, Volume: 7, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati

1989
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci

1989
[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
    Geburtshilfe und Frauenheilkunde, 1989, Volume: 49, Issue:12

    Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo

1989
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer.
    Cancer treatment reports, 1987, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1987
[Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1988
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
    Onkologie, 1988, Volume: 11 Suppl 2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun

1988
[Hepatotoxicity with etoposide-ifosfamide combination therapy].
    Onkologie, 1988, Volume: 11, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cel

1988
Failure of response to ifosfamide in squamous cell bronchogenic carcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:2

    Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Drug Resistance; Humans; Ifosfamide; Lung Neoplas

1989
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
    Strahlentherapie, 1985, Volume: 161, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic

1985
[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma].
    Onkologie, 1985, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug

1985
Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell;

1986
Phase II study of ifosfamide in cervical cancer.
    Cancer treatment reports, 1986, Volume: 70, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo

1986
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.
    Investigational new drugs, 1988, Volume: 6, Issue:3

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Hematologic Te

1988
Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Head and Neck Neoplasms; Humans; Ifosfamide;

1988
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;

1986